

Dsire M Van Der Heijde

List of Publications by Citations

Source: <https://exaly.com/author-pdf/5162906/desiree-m-van-der-heijde-publications-by-citations.pdf>

Version: 2024-04-25

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

765
papers

61,849
citations

127
h-index

232
g-index

844
ext. papers

74,045
ext. citations

4.1
avg, IF

7.5
L-index

#	Paper	IF	Citations
765	The development of Assessment of SpondyloArthritis international Society classification criteria for axial spondyloarthritis (part II): validation and final selection. <i>Annals of the Rheumatic Diseases</i> , 2009 , 68, 777-83	2.4	1918
764	EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update. <i>Annals of the Rheumatic Diseases</i> , 2017 , 76, 960-977	2.4	1649
763	EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update. <i>Annals of the Rheumatic Diseases</i> , 2014 , 73, 492-509	2.4	1487
762	Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised controlled trial. <i>Lancet, The</i> , 2004 , 363, 675-81	4.0	1454
761	EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs. <i>Annals of the Rheumatic Diseases</i> , 2010 , 69, 964-75	2.4	1210
760	The Assessment of SpondyloArthritis International Society classification criteria for peripheral spondyloarthritis and for spondyloarthritis in general. <i>Annals of the Rheumatic Diseases</i> , 2011 , 70, 25-31	2.4	919
759	EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update. <i>Annals of the Rheumatic Diseases</i> , 2020 , 79, 685-699	2.4	851
758	Treating rheumatoid arthritis to target: 2014 update of the recommendations of an international task force. <i>Annals of the Rheumatic Diseases</i> , 2016 , 75, 3-15	2.4	814
757	2016 update of the ASAS-EULAR management recommendations for axial spondyloarthritis. <i>Annals of the Rheumatic Diseases</i> , 2017 , 76, 978-991	2.4	801
756	The Assessment of SpondyloArthritis international Society (ASAS) handbook: a guide to assess spondyloarthritis. <i>Annals of the Rheumatic Diseases</i> , 2009 , 68 Suppl 2, ii1-44	2.4	800
755	2010 update of the ASAS/EULAR recommendations for the management of ankylosing spondylitis. <i>Annals of the Rheumatic Diseases</i> , 2011 , 70, 896-904	2.4	681
754	Efficacy and safety of infliximab in patients with ankylosing spondylitis: results of a randomized, placebo-controlled trial (ASSERT). <i>Arthritis and Rheumatism</i> , 2005 , 52, 582-91		651
753	Efficacy and safety of adalimumab in patients with ankylosing spondylitis: results of a multicenter, randomized, double-blind, placebo-controlled trial. <i>Arthritis and Rheumatism</i> , 2006 , 54, 2136-46		630
752	European League Against Rheumatism (EULAR) recommendations for the management of psoriatic arthritis with pharmacological therapies: 2015 update. <i>Annals of the Rheumatic Diseases</i> , 2016 , 75, 499-510	2.4	611
751	Recombinant human tumor necrosis factor receptor (etanercept) for treating ankylosing spondylitis: a randomized, controlled trial. <i>Arthritis and Rheumatism</i> , 2003 , 48, 3230-6		607
750	Secukinumab, a human anti-interleukin-17A monoclonal antibody, in patients with psoriatic arthritis (FUTURE 2): a randomised, double-blind, placebo-controlled, phase 3 trial. <i>Lancet, The</i> , 2015 , 386, 1137-46	4.0	566
749	Study of active controlled monotherapy used for rheumatoid arthritis, an IL-6 inhibitor (SAMURAI): evidence of clinical and radiographic benefit from an x ray reader-blinded randomised controlled trial of tocilizumab. <i>Annals of the Rheumatic Diseases</i> , 2007 , 66, 1162-7	2.4	562

748	Age at disease onset and diagnosis delay in HLA-B27 negative vs. positive patients with ankylosing spondylitis. <i>Rheumatology International</i> , 2003 , 23, 61-6	3.6	562
747	The development of Assessment of SpondyloArthritis international Society classification criteria for axial spondyloarthritis (part I): classification of paper patients by expert opinion including uncertainty appraisal. <i>Annals of the Rheumatic Diseases</i> , 2009 , 68, 770-6	2.4	543
746	Defining active sacroiliitis on magnetic resonance imaging (MRI) for classification of axial spondyloarthritis: a consensual approach by the ASAS/OMERACT MRI group. <i>Annals of the Rheumatic Diseases</i> , 2009 , 68, 1520-7	2.4	538
745	Development of an ASAS-endorsed disease activity score (ASDAS) in patients with ankylosing spondylitis. <i>Annals of the Rheumatic Diseases</i> , 2009 , 68, 18-24	2.4	536
744	American College of Rheumatology/European League Against Rheumatism provisional definition of remission in rheumatoid arthritis for clinical trials. <i>Arthritis and Rheumatism</i> , 2011 , 63, 573-86		520
743	American College of Rheumatology/European League against Rheumatism provisional definition of remission in rheumatoid arthritis for clinical trials. <i>Annals of the Rheumatic Diseases</i> , 2011 , 70, 404-13	2.4	518
742	Secukinumab Inhibition of Interleukin-17A in Patients with Psoriatic Arthritis. <i>New England Journal of Medicine</i> , 2015 , 373, 1329-39	59.2	508
741	Nonsteroidal antiinflammatory drugs reduce radiographic progression in patients with ankylosing spondylitis: a randomized clinical trial. <i>Arthritis and Rheumatism</i> , 2005 , 52, 1756-65		492
740	Ankylosing spondylitis assessment group preliminary definition of short-term improvement in ankylosing spondylitis. <i>Arthritis and Rheumatism</i> , 2001 , 44, 1876-86		468
739	How to read radiographs according to the Sharp/van der Heijde method. <i>Journal of Rheumatology</i> , 2000 , 27, 261-3	4.1	460
738	Certolizumab pegol plus methotrexate is significantly more effective than placebo plus methotrexate in active rheumatoid arthritis: findings of a fifty-two-week, phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group study. <i>Arthritis and Rheumatism</i> , 2008 , 58, 3319-29		458
737	Anti-interleukin-17A monoclonal antibody secukinumab in treatment of ankylosing spondylitis: a randomised, double-blind, placebo-controlled trial. <i>Lancet, The</i> , 2013 , 382, 1705-13	40	449
736	Denosumab treatment effects on structural damage, bone mineral density, and bone turnover in rheumatoid arthritis: a twelve-month, multicenter, randomized, double-blind, placebo-controlled, phase II clinical trial. <i>Arthritis and Rheumatism</i> , 2008 , 58, 1299-309		441
735	ASAS/EULAR recommendations for the management of ankylosing spondylitis. <i>Annals of the Rheumatic Diseases</i> , 2006 , 65, 442-52	2.4	431
734	Efficacy and safety of golimumab in patients with ankylosing spondylitis: results of a randomized, double-blind, placebo-controlled, phase III trial. <i>Arthritis and Rheumatism</i> , 2008 , 58, 3402-12		428
733	Baricitinib versus Placebo or Adalimumab in Rheumatoid Arthritis. <i>New England Journal of Medicine</i> , 2017 , 376, 652-662	59.2	427
732	Radiographic progression of ankylosing spondylitis after up to two years of treatment with etanercept. <i>Arthritis and Rheumatism</i> , 2008 , 58, 1324-31		427
731	Comparison of etanercept and methotrexate, alone and combined, in the treatment of rheumatoid arthritis: two-year clinical and radiographic results from the TEMPO study, a double-blind, randomized trial. <i>Arthritis and Rheumatism</i> , 2006 , 54, 1063-74		407

730	Ankylosing Spondylitis Disease Activity Score (ASDAS): defining cut-off values for disease activity states and improvement scores. <i>Annals of the Rheumatic Diseases</i> , 2011 , 70, 47-53	2.4	404
729	Tofacitinib (CP-690,550) in patients with rheumatoid arthritis receiving methotrexate: twelve-month data from a twenty-four-month phase III randomized radiographic study. <i>Arthritis and Rheumatism</i> , 2013 , 65, 559-70		402
728	Radiographic findings following two years of infliximab therapy in patients with ankylosing spondylitis. <i>Arthritis and Rheumatism</i> , 2008 , 58, 3063-70		399
727	How to diagnose axial spondyloarthritis early. <i>Annals of the Rheumatic Diseases</i> , 2004 , 63, 535-43	2.4	398
726	Assessment of enthesitis in ankylosing spondylitis. <i>Annals of the Rheumatic Diseases</i> , 2003 , 62, 127-32	2.4	393
725	Development of the ASQoL: a quality of life instrument specific to ankylosing spondylitis. <i>Annals of the Rheumatic Diseases</i> , 2003 , 62, 20-6	2.4	378
724	EULAR recommendations for the use of imaging of the joints in the clinical management of rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2013 , 72, 804-14	2.4	376
723	European League Against Rheumatism recommendations for the management of psoriatic arthritis with pharmacological therapies. <i>Annals of the Rheumatic Diseases</i> , 2012 , 71, 4-12	2.4	355
722	ASDAS, a highly discriminatory ASAS-endorsed disease activity score in patients with ankylosing spondylitis. <i>Annals of the Rheumatic Diseases</i> , 2009 , 68, 1811-8	2.4	349
721	Efficacy and safety of adalimumab in patients with non-radiographic axial spondyloarthritis: results of a randomised placebo-controlled trial (ABILITY-1). <i>Annals of the Rheumatic Diseases</i> , 2013 , 72, 815-22	2.4	347
720	New criteria for inflammatory back pain in patients with chronic back pain: a real patient exercise by experts from the Assessment of SpondyloArthritis international Society (ASAS). <i>Annals of the Rheumatic Diseases</i> , 2009 , 68, 784-8	2.4	347
719	Ixekizumab, an interleukin-17A specific monoclonal antibody, for the treatment of biologic-naïve patients with active psoriatic arthritis: results from the 24-week randomised, double-blind, placebo-controlled and active (adalimumab)-controlled period of the phase III trial SPIRIT-P1.	2.4	341
718	Evidence of radiographic benefit of treatment with infliximab plus methotrexate in rheumatoid arthritis patients who had no clinical improvement: a detailed subanalysis of data from the anti-tumor necrosis factor trial in rheumatoid arthritis with concomitant therapy study. <i>Arthritis and Rheumatism</i> , 2005 , 52, 1020-30		340
717	Efficacy and safety of certolizumab pegol plus methotrexate in active rheumatoid arthritis: the RAPID 2 study. A randomised controlled trial. <i>Annals of the Rheumatic Diseases</i> , 2009 , 68, 797-804	2.4	339
716	Effect of certolizumab pegol on signs and symptoms in patients with psoriatic arthritis: 24-week results of a Phase 3 double-blind randomised placebo-controlled study (RAPID-PsA). <i>Annals of the Rheumatic Diseases</i> , 2014 , 73, 48-55	2.4	328
715	Treating axial spondyloarthritis and peripheral spondyloarthritis, especially psoriatic arthritis, to target: 2017 update of recommendations by an international task force. <i>Annals of the Rheumatic Diseases</i> , 2018 , 77, 3-17	2.4	320
714	Multinational evidence-based recommendations for the use of methotrexate in rheumatic disorders with a focus on rheumatoid arthritis: integrating systematic literature research and expert opinion of a broad international panel of rheumatologists in the 3E Initiative. <i>Annals of the Rheumatic Diseases</i> , 2009 , 68, 1086-93	2.4	320
713	How to read radiographs according to the Sharp/van der Heijde method. <i>Journal of Rheumatology</i> , 1999 , 26, 743-5	4.1	310

712	Treating spondyloarthritis, including ankylosing spondylitis and psoriatic arthritis, to target: recommendations of an international task force. <i>Annals of the Rheumatic Diseases</i> , 2014 , 73, 6-16	2.4	308
711	Updated consensus statement on the use of rituximab in patients with rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2011 , 70, 909-20	2.4	308
710	2010 Update of the international ASAS recommendations for the use of anti-TNF agents in patients with axial spondyloarthritis. <i>Annals of the Rheumatic Diseases</i> , 2011 , 70, 905-8	2.4	302
709	Efficacy of certolizumab pegol on signs and symptoms of axial spondyloarthritis including ankylosing spondylitis: 24-week results of a double-blind randomised placebo-controlled Phase 3 study. <i>Annals of the Rheumatic Diseases</i> , 2014 , 73, 39-47	2.4	301
708	Magnetic resonance imaging examinations of the spine in patients with ankylosing spondylitis, before and after successful therapy with infliximab: evaluation of a new scoring system. <i>Arthritis and Rheumatism</i> , 2003 , 48, 1126-36		301
707	Tofacitinib or Adalimumab versus Placebo for Psoriatic Arthritis. <i>New England Journal of Medicine</i> , 2017 , 377, 1537-1550	59.2	297
706	Assessment of radiographic progression in the spines of patients with ankylosing spondylitis treated with adalimumab for up to 2 years. <i>Arthritis Research and Therapy</i> , 2009 , 11, R127	5.7	297
705	EULAR recommendations for the use of imaging in the diagnosis and management of spondyloarthritis in clinical practice. <i>Annals of the Rheumatic Diseases</i> , 2015 , 74, 1327-39	2.4	284
704	A randomized comparative effectiveness study of oral triple therapy versus etanercept plus methotrexate in early aggressive rheumatoid arthritis: the treatment of Early Aggressive Rheumatoid Arthritis Trial. <i>Arthritis and Rheumatism</i> , 2012 , 64, 2824-35		271
703	Efficacy and safety of secukinumab, a fully human anti-interleukin-17A monoclonal antibody, in patients with moderate-to-severe psoriatic arthritis: a 24-week, randomised, double-blind, placebo-controlled, phase II proof-of-concept trial. <i>Annals of the Rheumatic Diseases</i> , 2014 , 73, 349-56	2.4	267
702	Safety of synthetic and biological DMARDs: a systematic literature review informing the 2013 update of the EULAR recommendations for management of rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2014 , 73, 529-35	2.4	266
701	International ASAS consensus statement for the use of anti-tumour necrosis factor agents in patients with ankylosing spondylitis. <i>Annals of the Rheumatic Diseases</i> , 2003 , 62, 817-24	2.4	262
700	Defining active sacroiliitis on MRI for classification of axial spondyloarthritis: update by the ASAS MRI working group. <i>Annals of the Rheumatic Diseases</i> , 2016 , 75, 1958-1963	2.4	259
699	EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2019 update. <i>Annals of the Rheumatic Diseases</i> , 2020 , 79, 700-712	2.4	238
698	High anti-cyclic citrullinated peptide levels and an algorithm of four variables predict radiographic progression in patients with rheumatoid arthritis: results from a 10-year longitudinal study. <i>Annals of the Rheumatic Diseases</i> , 2008 , 67, 212-7	2.4	233
697	First update of the international ASAS consensus statement for the use of anti-TNF agents in patients with ankylosing spondylitis. <i>Annals of the Rheumatic Diseases</i> , 2006 , 65, 316-20	2.4	229
696	Minimum clinically important improvement and patient acceptable symptom state in pain and function in rheumatoid arthritis, ankylosing spondylitis, chronic back pain, hand osteoarthritis, and hip and knee osteoarthritis: Results from a prospective multinational study. <i>Arthritis Care and Research</i> , 2012 , 64, 1699-707	4.7	226
695	Baricitinib in patients with inadequate response or intolerance to conventional synthetic DMARDs: results from the RA-BUILD study. <i>Annals of the Rheumatic Diseases</i> , 2017 , 76, 88-95	2.4	222

694	Baricitinib, Methotrexate, or Combination in Patients With Rheumatoid Arthritis and No or Limited Prior Disease-Modifying Antirheumatic Drug Treatment. <i>Arthritis and Rheumatology</i> , 2017 , 69, 506-517	9.5	216
693	Safety of synthetic and biological DMARDs: a systematic literature review informing the 2016 update of the EULAR recommendations for management of rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2017 , 76, 1101-1136	2.4	213
692	A systematic literature review of drug therapies for the treatment of psoriatic arthritis: current evidence and meta-analysis informing the EULAR recommendations for the management of psoriatic arthritis. <i>Annals of the Rheumatic Diseases</i> , 2012 , 71, 319-26	2.4	201
691	Deciding on progression of joint damage in paired films of individual patients: smallest detectable difference or change. <i>Annals of the Rheumatic Diseases</i> , 2005 , 64, 179-82	2.4	200
690	Optimal dosage and route of administration of methotrexate in rheumatoid arthritis: a systematic review of the literature. <i>Annals of the Rheumatic Diseases</i> , 2009 , 68, 1094-9	2.4	199
689	Tofacitinib in patients with ankylosing spondylitis: a phase II, 16-week, randomised, placebo-controlled, dose-ranging study. <i>Annals of the Rheumatic Diseases</i> , 2017 , 76, 1340-1347	2.4	198
688	Head-to-head comparison of subcutaneous abatacept versus adalimumab for rheumatoid arthritis: two-year efficacy and safety findings from AMPLE trial. <i>Annals of the Rheumatic Diseases</i> , 2014 , 73, 86-94	2.4	197
687	Higher disease activity leads to more structural damage in the spine in ankylosing spondylitis: 12-year longitudinal data from the OASIS cohort. <i>Annals of the Rheumatic Diseases</i> , 2014 , 73, 1455-61	2.4	190
686	Head-to-head comparison of subcutaneous abatacept versus adalimumab for rheumatoid arthritis: findings of a phase IIIb, multinational, prospective, randomized study. <i>Arthritis and Rheumatism</i> , 2013 , 65, 28-38		186
685	Continuous NSAID use reverts the effects of inflammation on radiographic progression in patients with ankylosing spondylitis. <i>Annals of the Rheumatic Diseases</i> , 2012 , 71, 1623-9	2.4	182
684	Both structural damage and inflammation of the spine contribute to impairment of spinal mobility in patients with ankylosing spondylitis. <i>Annals of the Rheumatic Diseases</i> , 2010 , 69, 1465-70	2.4	181
683	Major reduction in spinal inflammation in patients with ankylosing spondylitis after treatment with infliximab: results of a multicenter, randomized, double-blind, placebo-controlled magnetic resonance imaging study. <i>Arthritis and Rheumatism</i> , 2006 , 54, 1646-52		180
682	Relative value of erythrocyte sedimentation rate and C-reactive protein in assessment of disease activity in ankylosing spondylitis. <i>Journal of Rheumatology</i> , 1999 , 26, 980-4	4.1	180
681	Efficacy of celecoxib, a cyclooxygenase 2-specific inhibitor, in the treatment of ankylosing spondylitis: a six-week controlled study with comparison against placebo and against a conventional nonsteroidal antiinflammatory drug. <i>Arthritis and Rheumatism</i> , 2001 , 44, 180-5		177
680	Selection of instruments in the core set for DC-ART, SMARD, physical therapy, and clinical record keeping in ankylosing spondylitis. Progress report of the ASAS Working Group. Assessments in Ankylosing Spondylitis. <i>Journal of Rheumatology</i> , 1999 , 26, 951-4	4.1	173
679	Disease remission and sustained halting of radiographic progression with combination etanercept and methotrexate in patients with rheumatoid arthritis. <i>Arthritis and Rheumatism</i> , 2007 , 56, 3928-39		171
678	Evidence for treating rheumatoid arthritis to target: results of a systematic literature search. <i>Annals of the Rheumatic Diseases</i> , 2010 , 69, 638-643	2.4	168
677	The DESIR cohort: a 10-year follow-up of early inflammatory back pain in France: study design and baseline characteristics of the 708 recruited patients. <i>Joint Bone Spine</i> , 2011 , 78, 598-603	2.9	165

676	Ixekizumab, an interleukin-17A antagonist in the treatment of ankylosing spondylitis or radiographic axial spondyloarthritis in patients previously untreated with biological disease-modifying anti-rheumatic drugs (COAST-V): 16 week results of a phase 3 randomised, double-blind, active-controlled and placebo-controlled trial. <i>Lancet, The</i> , 2018 , 392, 2441-2451	4.0	161
675	Sarilumab Plus Methotrexate in Patients With Active Rheumatoid Arthritis and Inadequate Response to Methotrexate: Results of a Phase III Study. <i>Arthritis and Rheumatology</i> , 2015 , 67, 1424-37	9.5	158
674	Evidence for treating rheumatoid arthritis to target: results of a systematic literature search update. <i>Annals of the Rheumatic Diseases</i> , 2016 , 75, 16-22	2.4	156
673	ASAS recommendations for collecting, analysing and reporting NSAID intake in clinical trials/epidemiological studies in axial spondyloarthritis. <i>Annals of the Rheumatic Diseases</i> , 2011 , 70, 249-54	3.4	156
672	Proposal for a new nomenclature of disease-modifying antirheumatic drugs. <i>Annals of the Rheumatic Diseases</i> , 2014 , 73, 3-5	2.4	155
671	Prevalence of and predictive factors for sustained disease-modifying antirheumatic drug-free remission in rheumatoid arthritis: results from two large early arthritis cohorts. <i>Arthritis and Rheumatism</i> , 2009 , 60, 2262-71		154
670	Three Multicenter, Randomized, Double-Blind, Placebo-Controlled Studies Evaluating the Efficacy and Safety of Ustekinumab in Axial Spondyloarthritis. <i>Arthritis and Rheumatology</i> , 2019 , 71, 258-270	9.5	153
669	Golimumab in psoriatic arthritis: one-year clinical efficacy, radiographic, and safety results from a phase III, randomized, placebo-controlled trial. <i>Arthritis and Rheumatism</i> , 2012 , 64, 2504-17		151
668	Evaluation of the efficacy of etoricoxib in ankylosing spondylitis: results of a fifty-two-week, randomized, controlled study. <i>Arthritis and Rheumatism</i> , 2005 , 52, 1205-15		151
667	Validity, reliability and responsiveness of the Work Productivity and Activity Impairment Questionnaire in ankylosing spondylitis. <i>Rheumatology</i> , 2010 , 49, 812-9	3.9	148
666	Physical function in ankylosing spondylitis is independently determined by both disease activity and radiographic damage of the spine. <i>Annals of the Rheumatic Diseases</i> , 2009 , 68, 863-7	2.4	146
665	Radiographic assessment of sacroiliitis by radiologists and rheumatologists: does training improve quality?. <i>Annals of the Rheumatic Diseases</i> , 2003 , 62, 519-25	2.4	144
664	Employment, work disability, and work days lost in patients with ankylosing spondylitis: a cross sectional study of Dutch patients. <i>Annals of the Rheumatic Diseases</i> , 2001 , 60, 353-8	2.4	144
663	Consensus on a core set of domains for psoriatic arthritis. <i>Journal of Rheumatology</i> , 2007 , 34, 1167-70	4.1	144
662	Efficacy of biological disease-modifying antirheumatic drugs: a systematic literature review informing the 2016 update of the EULAR recommendations for the management of rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2017 , 76, 1113-1136	2.4	143
661	TNF blockers inhibit spinal radiographic progression in ankylosing spondylitis by reducing disease activity: results from the Swiss Clinical Quality Management cohort. <i>Annals of the Rheumatic Diseases</i> , 2018 , 77, 63-69	2.4	143
660	2014 Update of the EULAR standardised operating procedures for EULAR-endorsed recommendations. <i>Annals of the Rheumatic Diseases</i> , 2015 , 74, 8-13	2.4	143
659	Infliximab inhibits progression of radiographic damage in patients with active psoriatic arthritis through one year of treatment: Results from the induction and maintenance psoriatic arthritis clinical trial 2. <i>Arthritis and Rheumatism</i> , 2007 , 56, 2698-707		143

658	Symptomatic efficacy of etanercept and its effects on objective signs of inflammation in early nonradiographic axial spondyloarthritis: a multicenter, randomized, double-blind, placebo-controlled trial. <i>Arthritis and Rheumatology</i> , 2014 , 66, 2091-102	9.5	141
657	Association of baseline levels of markers of bone and cartilage degradation with long-term progression of joint damage in patients with early rheumatoid arthritis: the COBRA study. <i>Arthritis and Rheumatism</i> , 2002 , 46, 2847-56		141
656	Work status and productivity costs due to ankylosing spondylitis: comparison of three European countries. <i>Annals of the Rheumatic Diseases</i> , 2002 , 61, 429-37	2.4	141
655	Prevalence of comorbidities and evaluation of their screening in spondyloarthritis: results of the international cross-sectional ASAS-COMOSPA study. <i>Annals of the Rheumatic Diseases</i> , 2016 , 75, 1016-23	2.4	139
654	A randomized, double-blind, placebo-controlled, sixteen-week study of subcutaneous golimumab in patients with active nonradiographic axial spondyloarthritis. <i>Arthritis and Rheumatology</i> , 2015 , 67, 2702-12	2.5	139
653	Differences in the incidence of flares or new onset of inflammatory bowel diseases in patients with ankylosing spondylitis exposed to therapy with anti-tumor necrosis factor alpha agents. <i>Arthritis and Rheumatism</i> , 2007 , 57, 639-47		139
652	Development and preselection of criteria for short term improvement after anti-TNF alpha treatment in ankylosing spondylitis. <i>Annals of the Rheumatic Diseases</i> , 2004 , 63, 1438-44	2.4	139
651	Preliminary core sets for endpoints in ankylosing spondylitis. Assessments in Ankylosing Spondylitis Working Group. <i>Journal of Rheumatology</i> , 1997 , 24, 2225-9	4.1	137
650	Ultrasound in management of rheumatoid arthritis: ARCTIC randomised controlled strategy trial. <i>BMJ, The</i> , 2016 , 354, i4205	5.9	136
649	Disconnect between inflammation and joint destruction after treatment with etanercept plus methotrexate: results from the trial of etanercept and methotrexate with radiographic and patient outcomes. <i>Arthritis and Rheumatism</i> , 2006 , 54, 3119-25		136
648	Current evidence for the management of ankylosing spondylitis: a systematic literature review for the ASAS/EULAR management recommendations in ankylosing spondylitis. <i>Annals of the Rheumatic Diseases</i> , 2006 , 65, 423-32	2.4	133
647	Withdrawal from labour force due to work disability in patients with ankylosing spondylitis. <i>Annals of the Rheumatic Diseases</i> , 2001 , 60, 1033-9	2.4	133
646	Secukinumab improves active psoriatic arthritis symptoms and inhibits radiographic progression: primary results from the randomised, double-blind, phase III FUTURE 5 study. <i>Annals of the Rheumatic Diseases</i> , 2018 , 77, 890-897	2.4	132
645	Reporting disease activity in clinical trials of patients with rheumatoid arthritis: EULAR/ACR collaborative recommendations. <i>Annals of the Rheumatic Diseases</i> , 2008 , 67, 1360-4	2.4	132
644	The Infliximab Multinational Psoriatic Arthritis Controlled Trial (IMPACT): results of radiographic analyses after 1 year. <i>Annals of the Rheumatic Diseases</i> , 2006 , 65, 1038-43	2.4	132
643	Efficacy and safety of abatacept, a T-cell modulator, in a randomised, double-blind, placebo-controlled, phase III study in psoriatic arthritis. <i>Annals of the Rheumatic Diseases</i> , 2017 , 76, 1550-58	2.4	129
642	Targeting ultrasound remission in early rheumatoid arthritis: the results of the TaSER study, a randomised clinical trial. <i>Annals of the Rheumatic Diseases</i> , 2016 , 75, 1043-50	2.4	129
641	Evolution of radiographic damage in ankylosing spondylitis: a 12 year prospective follow-up of the OASIS study. <i>Annals of the Rheumatic Diseases</i> , 2015 , 74, 52-9	2.4	127

640	The role of methotrexate co-medication in TNF-inhibitor treatment in patients with psoriatic arthritis: results from 440 patients included in the NOR-DMARD study. <i>Annals of the Rheumatic Diseases</i> , 2014 , 73, 132-7	2.4	127
639	Serum matrix metalloproteinase 3 is an independent predictor of structural damage progression in patients with ankylosing spondylitis. <i>Arthritis and Rheumatism</i> , 2007 , 56, 1846-53		127
638	Quality of life in rheumatoid arthritis. <i>Rheumatology</i> , 1997 , 36, 884-8	3.9	125
637	Predicting the outcome of ankylosing spondylitis therapy. <i>Annals of the Rheumatic Diseases</i> , 2011 , 70, 973-81	2.4	124
636	Evaluation of several ultrasonography scoring systems for synovitis and comparison to clinical examination: results from a prospective multicentre study of rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2010 , 69, 828-33	2.4	123
635	Analysing chronic spinal changes in ankylosing spondylitis: a systematic comparison of conventional x rays with magnetic resonance imaging using established and new scoring systems. <i>Annals of the Rheumatic Diseases</i> , 2004 , 63, 1046-55	2.4	122
634	Review: Nonradiographic axial spondyloarthritis: new definition of an old disease?. <i>Arthritis and Rheumatism</i> , 2013 , 65, 543-51		121
633	Points to consider for reporting, screening for and preventing selected comorbidities in chronic inflammatory rheumatic diseases in daily practice: a EULAR initiative. <i>Annals of the Rheumatic Diseases</i> , 2016 , 75, 965-73	2.4	121
632	Prevalence of peripheral and extra-articular disease in ankylosing spondylitis versus non-radiographic axial spondyloarthritis: a meta-analysis. <i>Arthritis Research and Therapy</i> , 2016 , 18, 196	5.7	120
631	Percentage of patients with spondyloarthritis in patients referred because of chronic back pain and performance of classification criteria: experience from the Spondyloarthritis Caught Early (SPACE) cohort. <i>Rheumatology</i> , 2013 , 52, 1492-9	3.9	120
630	Efficacy and safety of filgotinib, a selective Janus kinase 1 inhibitor, in patients with active ankylosing spondylitis (TORTUGA): results from a randomised, placebo-controlled, phase 2 trial. <i>Lancet, The</i> , 2018 , 392, 2378-2387	4.0	120
629	The Stop Arthritis Very Early (SAVE) trial, an international multicentre, randomised, double-blind, placebo-controlled trial on glucocorticoids in very early arthritis. <i>Annals of the Rheumatic Diseases</i> , 2010 , 69, 495-502	2.4	117
628	Assessment of fatigue in patients with ankylosing spondylitis: a psychometric analysis. <i>Arthritis and Rheumatism</i> , 2002 , 47, 8-16		117
627	Adalimumab effectiveness for the treatment of ankylosing spondylitis is maintained for up to 2 years: long-term results from the ATLAS trial. <i>Annals of the Rheumatic Diseases</i> , 2009 , 68, 922-9	2.4	116
626	Smokers in early axial spondyloarthritis have earlier disease onset, more disease activity, inflammation and damage, and poorer function and health-related quality of life: results from the DESIR cohort. <i>Annals of the Rheumatic Diseases</i> , 2012 , 71, 809-16	2.4	114
625	How to report radiographic data in randomized clinical trials in rheumatoid arthritis: guidelines from a roundtable discussion. <i>Arthritis and Rheumatism</i> , 2002 , 47, 215-8		114
624	Safety of synthetic and biological DMARDs: a systematic literature review informing the 2019 update of the EULAR recommendations for the management of rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2020 , 79, 760-770	2.4	112
623	Which spinal lesions are associated with new bone formation in patients with ankylosing spondylitis treated with anti-TNF agents? A long-term observational study using MRI and conventional radiography. <i>Annals of the Rheumatic Diseases</i> , 2014 , 73, 1819-25	2.4	111

622	Determination of the minimal clinically important difference in rheumatoid arthritis joint damage of the Sharp/van der Heijde and Larsen/Scott scoring methods by clinical experts and comparison with the smallest detectable difference. <i>Arthritis and Rheumatism</i> , 2002 , 46, 913-20		111
621	Effect of denosumab on Japanese patients with rheumatoid arthritis: a dose-response study of AMG 162 (Denosumab) in patients with Rheumatoid arthritis on methotrexate to Validate inhibitory effect on bone Erosion (DRIVE)-a 12-month, multicentre, randomised, double-blind, placebo-controlled, phase II clinical trial. <i>Annals of the Rheumatic Diseases</i> , 2016 , 75, 983-90	2.4	111
620	Tumor necrosis factor inhibition in radiographic and nonradiographic axial spondyloarthritis: results from a large observational cohort. <i>Arthritis and Rheumatism</i> , 2013 , 65, 3096-106		109
619	MRI in early rheumatoid arthritis: synovitis and bone marrow oedema are independent predictors of subsequent radiographic progression. <i>Annals of the Rheumatic Diseases</i> , 2011 , 70, 428-33	2.4	108
618	Magnetic Resonance Imaging of the Sacroiliac Joints Indicating Sacroiliitis According to the Assessment of SpondyloArthritis international Society Definition in Healthy Individuals, Runners, and Women With Postpartum Back Pain. <i>Arthritis and Rheumatology</i> , 2018 , 70, 1042-1048	9.5	107
617	Inflammatory biomarkers, disease activity and spinal disease measures in patients with ankylosing spondylitis after treatment with infliximab. <i>Annals of the Rheumatic Diseases</i> , 2008 , 67, 511-7	2.4	107
616	Prediction of radiographic progression in rheumatoid arthritis and the role of antibodies against mutated citrullinated vimentin: results from a 10-year prospective study. <i>Annals of the Rheumatic Diseases</i> , 2010 , 69, 345-51	2.4	106
615	Efficacy and safety of upadacitinib in patients with active ankylosing spondylitis (SELECT-AXIS 1): a multicentre, randomised, double-blind, placebo-controlled, phase 2/3 trial. <i>Lancet, The</i> , 2019 , 394, 2108-2117	4.9	104
614	Development of new syndesmophytes and bridges in ankylosing spondylitis and their predictors: a longitudinal study. <i>Annals of the Rheumatic Diseases</i> , 2012 , 71, 518-23	2.4	103
613	Assessment of acute spinal inflammation in patients with ankylosing spondylitis by magnetic resonance imaging: a comparison between contrast enhanced T1 and short tau inversion recovery (STIR) sequences. <i>Annals of the Rheumatic Diseases</i> , 2005 , 64, 1141-4	2.4	103
612	ASAS modification of the Berlin algorithm for diagnosing axial spondyloarthritis: results from the SPondyloArthritis Caught Early (SPACE)-cohort and from the Assessment of SpondyloArthritis international Society (ASAS)-cohort. <i>Annals of the Rheumatic Diseases</i> , 2013 , 72, 1646-53	2.4	102
611	Agreement between clinical practice and trained central reading in reading of sacroiliac joints on plain pelvic radiographs. Results from the DESIR cohort. <i>Arthritis and Rheumatology</i> , 2014 , 66, 2403-11	9.5	101
610	Molecular Portraits of Early Rheumatoid Arthritis Identify Clinical and Treatment Response Phenotypes. <i>Cell Reports</i> , 2019 , 28, 2455-2470.e5	10.6	100
609	Clinical efficacy, radiographic and safety findings through 5 years of subcutaneous golimumab treatment in patients with active psoriatic arthritis: results from a long-term extension of a randomised, placebo-controlled trial (the GO-REVEAL study). <i>Annals of the Rheumatic Diseases</i> , 2017 , 76, 1400-6	2.4	100
608	MRI inflammation at the vertebral unit only marginally predicts new syndesmophyte formation: a multilevel analysis in patients with ankylosing spondylitis. <i>Annals of the Rheumatic Diseases</i> , 2012 , 71, 369-73	2.4	99
607	Calprotectin (a major leucocyte protein) is strongly and independently correlated with joint inflammation and damage in rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2007 , 66, 1093-7	2.4	99
606	First update of the current evidence for the management of ankylosing spondylitis with non-pharmacological treatment and non-biologic drugs: a systematic literature review for the ASAS/EULAR management recommendations in ankylosing spondylitis. <i>Rheumatology</i> , 2012 , 51, 1388-96	3.9	98
605	Synovial cellular and molecular signatures stratify clinical response to csDMARD therapy and predict radiographic progression in early rheumatoid arthritis patients. <i>Annals of the Rheumatic Diseases</i> , 2019 , 78, 761-772	2.4	96

604	Development of a health index in patients with ankylosing spondylitis (ASAS HI): final result of a global initiative based on the ICF guided by ASAS. <i>Annals of the Rheumatic Diseases</i> , 2015 , 74, 830-5	2.4	96
603	Proposal of a linear definition of the Bath Ankylosing Spondylitis Metrology Index (BASMI) and comparison with the 2-step and 10-step definitions. <i>Annals of the Rheumatic Diseases</i> , 2008 , 67, 489-93	2.4	96
602	Association between radiographic damage of the spine and spinal mobility for individual patients with ankylosing spondylitis: can assessment of spinal mobility be a proxy for radiographic evaluation?. <i>Annals of the Rheumatic Diseases</i> , 2005 , 64, 988-94	2.4	96
601	Comparison of different definitions to classify remission and sustained remission: 1 year TEMPO results. <i>Annals of the Rheumatic Diseases</i> , 2005 , 64, 1582-7	2.4	96
600	Effects of infliximab on markers of inflammation and bone turnover and associations with bone mineral density in patients with ankylosing spondylitis. <i>Annals of the Rheumatic Diseases</i> , 2009 , 68, 175-82 ⁴	2.4	95
599	Ankylosing Spondylitis Disease Activity Score (ASDAS): 2018 update of the nomenclature for disease activity states. <i>Annals of the Rheumatic Diseases</i> , 2018 , 77, 1539-1540	2.4	94
598	HLA-B27 positive patients differ from HLA-B27 negative patients in clinical presentation and imaging: results from the DESIR cohort of patients with recent onset axial spondyloarthritis. <i>Annals of the Rheumatic Diseases</i> , 2011 , 70, 1930-6	2.4	94
597	Effectiveness of switching between TNF inhibitors in ankylosing spondylitis: data from the NOR-DMARD register. <i>Annals of the Rheumatic Diseases</i> , 2011 , 70, 157-63	2.4	91
596	Guselkumab in biologic-naive patients with active psoriatic arthritis (DISCOVER-2): a double-blind, randomised, placebo-controlled phase 3 trial. <i>Lancet, The</i> , 2020 , 395, 1126-1136	4.0	90
595	The effects of golimumab on radiographic progression in rheumatoid arthritis: results of randomized controlled studies of golimumab before methotrexate therapy and golimumab after methotrexate therapy. <i>Arthritis and Rheumatism</i> , 2011 , 63, 1200-10		90
594	Twenty-eight-joint counts invalidate the DAS28 remission definition owing to the omission of the lower extremity joints: a comparison with the original DAS remission. <i>Annals of the Rheumatic Diseases</i> , 2006 , 65, 637-41	2.4	90
593	Reading radiographs in chronological order, in pairs or as single films has important implications for the discriminative power of rheumatoid arthritis clinical trials. <i>Rheumatology</i> , 1999 , 38, 1213-20	3.9	90
592	Sacroiliac radiographic progression in recent onset axial spondyloarthritis: the 5-year data of the DESIR cohort. <i>Annals of the Rheumatic Diseases</i> , 2017 , 76, 1823-1828	2.4	89
591	Associations between MRI-defined synovitis, bone marrow lesions and structural features and measures of pain and physical function in hand osteoarthritis. <i>Annals of the Rheumatic Diseases</i> , 2012 , 71, 899-904	2.4	89
590	The effect of two golimumab doses on radiographic progression in ankylosing spondylitis: results through 4 years of the GO-RAISE trial. <i>Annals of the Rheumatic Diseases</i> , 2014 , 73, 1107-13	2.4	87
589	Consensus statement on blocking the effects of interleukin-6 and in particular by interleukin-6 receptor inhibition in rheumatoid arthritis and other inflammatory conditions. <i>Annals of the Rheumatic Diseases</i> , 2013 , 72, 482-92	2.4	87
588	Radiological scoring methods in ankylosing spondylitis. Reliability and change over 1 and 2 years. <i>Journal of Rheumatology</i> , 2004 , 31, 125-32	4.1	87
587	Pharmacological treatment of psoriatic arthritis: a systematic literature review for the 2015 update of the EULAR recommendations for the management of psoriatic arthritis. <i>Annals of the Rheumatic Diseases</i> , 2016 , 75, 490-8	2.4	86

586	The ability of synovitis to predict structural damage in rheumatoid arthritis: a comparative study between clinical examination and ultrasound. <i>Annals of the Rheumatic Diseases</i> , 2013 , 72, 665-71	2.4	86
585	Efficacy of glucocorticoids, conventional and targeted synthetic disease-modifying antirheumatic drugs: a systematic literature review informing the 2016 update of the EULAR recommendations for the management of rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2017 , 76, 1102-1107	2.4	85
584	EULAR definition of erosive disease in light of the 2010 ACR/EULAR rheumatoid arthritis classification criteria. <i>Annals of the Rheumatic Diseases</i> , 2013 , 72, 479-81	2.4	85
583	The burden of non-radiographic axial spondyloarthritis. <i>Seminars in Arthritis and Rheumatism</i> , 2015 , 44, 556-562	5.3	84
582	Combining information obtained from magnetic resonance imaging and conventional radiographs to detect sacroiliitis in patients with recent onset inflammatory back pain. <i>Annals of the Rheumatic Diseases</i> , 2006 , 65, 804-8	2.4	84
581	Impact of ankylosing spondylitis on sick leave, presenteeism and unpaid productivity, and estimation of the societal cost. <i>Annals of the Rheumatic Diseases</i> , 2010 , 69, 1123-8	2.4	82
580	MRI lesions in the sacroiliac joints of patients with spondyloarthritis: an update of definitions and validation by the ASAS MRI working group. <i>Annals of the Rheumatic Diseases</i> , 2019 , 78, 1550-1558	2.4	81
579	Evaluation and validation of the patient acceptable symptom state (PASS) in patients with ankylosing spondylitis. <i>Arthritis and Rheumatism</i> , 2007 , 57, 133-9		81
578	Effectiveness and retention rates of methotrexate in psoriatic arthritis in comparison with methotrexate-treated patients with rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2010 , 69, 671-6	2.4	80
577	Golimumab administered subcutaneously every 4 weeks in ankylosing spondylitis: 104-week results of the GO-RAISE study. <i>Annals of the Rheumatic Diseases</i> , 2012 , 71, 661-7	2.4	80
576	Scoring inflammatory activity of the spine by magnetic resonance imaging in ankylosing spondylitis: a multireader experiment. <i>Journal of Rheumatology</i> , 2007 , 34, 862-70	4.1	80
575	Direct costs of ankylosing spondylitis and its determinants: an analysis among three European countries. <i>Annals of the Rheumatic Diseases</i> , 2003 , 62, 732-40	2.4	79
574	Digital ulcers predict a worse disease course in patients with systemic sclerosis. <i>Annals of the Rheumatic Diseases</i> , 2016 , 75, 681-6	2.4	78
573	Calprotectin (a major S100 leucocyte protein) predicts 10-year radiographic progression in patients with rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2010 , 69, 150-4	2.4	77
572	Presentation and analysis of data on radiographic outcome in clinical trials: experience from the TEMPO study. <i>Arthritis and Rheumatism</i> , 2005 , 52, 49-60		77
571	Safety and efficacy of etanercept treatment in elderly subjects with rheumatoid arthritis. <i>Journal of Rheumatology</i> , 2006 , 33, 234-43	4.1	77
570	How much does Disease Activity Score in 28 joints ESR and CRP calculations underestimate disease activity compared with the Simplified Disease Activity Index?. <i>Annals of the Rheumatic Diseases</i> , 2015 , 74, 1132-7	2.4	75
569	Efficacy of pharmacological treatment in rheumatoid arthritis: a systematic literature research informing the 2019 update of the EULAR recommendations for management of rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2020 , 79, 744-759	2.4	75

568	Hand osteoarthritis and MRI: development and first validation step of the proposed Oslo Hand Osteoarthritis MRI score. <i>Annals of the Rheumatic Diseases</i> , 2011 , 70, 1033-8	2.4	75
567	Psoriatic arthritis imaging: a review of scoring methods. <i>Annals of the Rheumatic Diseases</i> , 2005 , 64 Suppl 2, ii61-4	2.4	75
566	Clinical presentation of patients suffering from recent onset chronic inflammatory back pain suggestive of spondyloarthritis: The DESIR cohort. <i>Joint Bone Spine</i> , 2015 , 82, 345-51	2.9	74
565	Efficacy and Safety of Ixekizumab in Patients with Active Psoriatic Arthritis: 52-week Results from a Phase III Study (SPIRIT-P1). <i>Journal of Rheumatology</i> , 2018 , 45, 367-377	4.1	74
564	Disease activity, physical function, and radiographic progression after longterm therapy with adalimumab plus methotrexate: 5-year results of PREMIER. <i>Journal of Rheumatology</i> , 2010 , 37, 2237-46	4.1	74
563	Ixekizumab for patients with non-radiographic axial spondyloarthritis (COAST-X): a randomised, placebo-controlled trial. <i>Lancet, The</i> , 2020 , 395, 53-64	4.0	74
562	Patients with chronic back pain of short duration from the SPACE cohort: which MRI structural lesions in the sacroiliac joints and inflammatory and structural lesions in the spine are most specific for axial spondyloarthritis?. <i>Annals of the Rheumatic Diseases</i> , 2016 , 75, 1308-14	2.4	73
561	Limited radiographic progression and sustained reductions in MRI inflammation in patients with axial spondyloarthritis: 4-year imaging outcomes from the RAPID-axSpA phase III randomised trial. <i>Annals of the Rheumatic Diseases</i> , 2018 , 77, 699-705	2.4	73
560	The concept of axial spondyloarthritis: joint statement of the spondyloarthritis research and treatment network and the Assessment of SpondyloArthritis international Society in response to the US Food and Drug Administration's comments and concerns. <i>Arthritis and Rheumatology</i> , 2014 , 66, 2649-56	9.5	72
559	ASAS/WHO ICF Core Sets for ankylosing spondylitis (AS): how to classify the impact of AS on functioning and health. <i>Annals of the Rheumatic Diseases</i> , 2010 , 69, 102-7	2.4	72
558	Monitoring anti-TNFalpha treatment in rheumatoid arthritis: responsiveness of magnetic resonance imaging and ultrasonography of the dominant wrist joint compared with conventional measures of disease activity and structural damage. <i>Annals of the Rheumatic Diseases</i> , 2009 , 68, 1572-9	2.4	72
557	Comparing the effects of tofacitinib, methotrexate and the combination, on bone marrow oedema, synovitis and bone erosion in methotrexate-naive, early active rheumatoid arthritis: results of an exploratory randomised MRI study incorporating semiquantitative and quantitative techniques. <i>Annals of the Rheumatic Diseases</i> , 2016 , 75, 1004-09	2.4	72
556	Development of an ASAS-endorsed recommendation for the early referral of patients with a suspicion of axial spondyloarthritis. <i>Annals of the Rheumatic Diseases</i> , 2015 , 74, 1483-7	2.4	71
555	Phase IIa, placebo-controlled, randomised study of lutikizumab, an anti-interleukin-1β and anti-interleukin-1β dual variable domain immunoglobulin, in patients with erosive hand osteoarthritis. <i>Annals of the Rheumatic Diseases</i> , 2019 , 78, 413-420	2.4	71
554	Clinical efficacy, radiographic and safety findings through 2 years of golimumab treatment in patients with active psoriatic arthritis: results from a long-term extension of the randomised, placebo-controlled GO-REVEAL study. <i>Annals of the Rheumatic Diseases</i> , 2013 , 72, 1777-85	2.4	70
553	Efficacy and safety of biological and targeted-synthetic DMARDs: a systematic literature review informing the 2016 update of the ASAS/EULAR recommendations for the management of axial spondyloarthritis. <i>RMD Open</i> , 2017 , 3, e000396	5.9	67
552	Updating the Psoriatic Arthritis (PsA) Core Domain Set: A Report from the PsA Workshop at OMERACT 2016. <i>Journal of Rheumatology</i> , 2017 , 44, 1522-1528	4.1	66
551	The first double-blind, randomised, parallel-group certolizumab pegol study in methotrexate-naive early rheumatoid arthritis patients with poor prognostic factors, C-OPERA, shows inhibition of radiographic progression. <i>Annals of the Rheumatic Diseases</i> , 2016 , 75, 75-83	2.4	66

550	Use of a numerical rating scale as an answer modality in ankylosing spondylitis-specific questionnaires. <i>Arthritis and Rheumatism</i> , 2002 , 47, 242-8		66
549	Magnetic resonance imaging of the sacroiliac joints in the early detection of spondyloarthritis: no added value of gadolinium compared with short tau inversion recovery sequence. <i>Rheumatology</i> , 2013 , 52, 1220-4	3.9	65
548	Early response to adalimumab predicts long-term remission through 5 years of treatment in patients with ankylosing spondylitis. <i>Annals of the Rheumatic Diseases</i> , 2012 , 71, 700-6	2.4	65
547	Clinical and MRI responses to etanercept in early non-radiographic axial spondyloarthritis: 48-week results from the EMBARK study. <i>Annals of the Rheumatic Diseases</i> , 2016 , 75, 1328-35	2.4	64
546	Golimumab reduces spinal inflammation in ankylosing spondylitis: MRI results of the randomised, placebo- controlled GO-RAISE study. <i>Annals of the Rheumatic Diseases</i> , 2012 , 71, 878-84	2.4	64
545	Development of multinational definitions of minimal clinically important improvement and patient acceptable symptomatic state in osteoarthritis. <i>Arthritis Care and Research</i> , 2015 , 67, 972-80	4.7	63
544	Efficacy and safety of peficitinib (ASP015K) in patients with rheumatoid arthritis and an inadequate response to methotrexate: results of a phase III randomised, double-blind, placebo-controlled trial (RAJ4) in Japan. <i>Annals of the Rheumatic Diseases</i> , 2019 , 78, 1305-1319	2.4	61
543	MRI vertebral corner inflammation followed by fat deposition is the strongest contributor to the development of new bone at the same vertebral corner: a multilevel longitudinal analysis in patients with ankylosing spondylitis. <i>Annals of the Rheumatic Diseases</i> , 2016 , 75, 1486-93	2.4	61
542	Effect of different imputation approaches on the evaluation of radiographic progression in patients with psoriatic arthritis: results of the RAPID-PsA 24-week phase III double-blind randomised placebo-controlled study of certolizumab pegol. <i>Annals of the Rheumatic Diseases</i> , 2014 , 73, 233-7	2.4	61
541	MRI inflammation and its relation with measures of clinical disease activity and different treatment responses in patients with ankylosing spondylitis treated with a tumour necrosis factor inhibitor. <i>Annals of the Rheumatic Diseases</i> , 2012 , 71, 2002-5	2.4	61
540	EULAR definition of difficult-to-treat rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2021 , 80, 31-35	2.4	61
539	Lifestyle factors may modify the effect of disease activity on radiographic progression in patients with ankylosing spondylitis: a longitudinal analysis. <i>RMD Open</i> , 2015 , 1, e000153	5.9	60
538	Impact of age, sex, physical function, health-related quality of life, and treatment with adalimumab on work status and work productivity of patients with ankylosing spondylitis. <i>Journal of Rheumatology</i> , 2010 , 37, 385-92	4.1	60
537	Detecting radiological changes in rheumatoid arthritis that are considered important by clinical experts: influence of reading with or without known sequence. <i>Journal of Rheumatology</i> , 2002 , 29, 2306-12	4.1	60
536	Serum 14-3-3 λ s a novel marker that complements current serological measurements to enhance detection of patients with rheumatoid arthritis. <i>Journal of Rheumatology</i> , 2014 , 41, 2104-13	4.1	59
535	Treating Rheumatoid Arthritis to Target: multinational recommendations assessment questionnaire. <i>Annals of the Rheumatic Diseases</i> , 2011 , 70, 1999-2002	2.4	59
534	Certolizumab pegol in combination with dose-optimised methotrexate in DMARD-naïve patients with early, active rheumatoid arthritis with poor prognostic factors: 1-year results from C-EARLY, a randomised, double-blind, placebo-controlled phase III study. <i>Annals of the Rheumatic Diseases</i> , 2017 , 76, 96-104	2.4	58
533	Level of radiographic damage and radiographic progression are determinants of physical function: a longitudinal analysis of the TEMPO trial. <i>Annals of the Rheumatic Diseases</i> , 2008 , 67, 1267-70	2.4	58

532	Radiographic Progression of Patients With Psoriatic Arthritis Who Achieve Minimal Disease Activity in Response to Golimumab Therapy: Results Through 5 Years of a Randomized, Placebo-Controlled Study. <i>Arthritis Care and Research</i> , 2016 , 68, 267-74	4.7	57
531	Cross-sectional and longitudinal associations between radiographic features and measures of pain and physical function in hand osteoarthritis. <i>Osteoarthritis and Cartilage</i> , 2013 , 21, 1191-8	6.2	57
530	Timing and magnitude of initial change in disease activity score 28 predicts the likelihood of achieving low disease activity at 1 year in rheumatoid arthritis patients treated with certolizumab pegol: a post-hoc analysis of the RAPID 1 trial. <i>Journal of Rheumatology</i> , 2012 , 39, 1326-33	4.1	57
529	Observed Incidence of Uveitis Following Certolizumab Pegol Treatment in Patients With Axial Spondyloarthritis. <i>Arthritis Care and Research</i> , 2016 , 68, 838-44	4.7	57
528	Brief Report: Secukinumab Provides Significant and Sustained Inhibition of Joint Structural Damage in a Phase III Study of Active Psoriatic Arthritis. <i>Arthritis and Rheumatology</i> , 2016 , 68, 1914-21	9.5	56
527	Golimumab administered subcutaneously every 4 weeks in ankylosing spondylitis: 5-year results of the GO-RAISE study. <i>Annals of the Rheumatic Diseases</i> , 2015 , 74, 757-61	2.4	56
526	Sustained efficacy, safety and patient-reported outcomes of certolizumab pegol in axial spondyloarthritis: 4-year outcomes from RAPID-axSpA. <i>Rheumatology</i> , 2017 , 56, 1498-1509	3.9	55
525	Update of the literature review on treatment with biologics as a basis for the first update of the ASAS/EULAR management recommendations of ankylosing spondylitis. <i>Rheumatology</i> , 2012 , 51, 1378-87	3.9	55
524	Effects of the anti-RANKL antibody denosumab on joint structural damage in patients with rheumatoid arthritis treated with conventional synthetic disease-modifying antirheumatic drugs (DESIRABLE study): a randomised, double-blind, placebo-controlled phase 3 trial. <i>Annals of the Rheumatic Diseases</i> , 2019 , 78, 899-907	2.4	54
523	Treating axial and peripheral spondyloarthritis, including psoriatic arthritis, to target: results of a systematic literature search to support an international treat-to-target recommendation in spondyloarthritis. <i>Annals of the Rheumatic Diseases</i> , 2014 , 73, 238-42	2.4	54
522	Health-related quality of life in patients with rheumatoid arthritis and in patients with ankylosing spondylitis. <i>Clinical and Experimental Rheumatology</i> , 2009 , 27, S108-11	2.2	54
521	Patients with seronegative RA have more inflammatory activity compared with patients with seropositive RA in an inception cohort of DMARD-naïve patients classified according to the 2010 ACR/EULAR criteria. <i>Annals of the Rheumatic Diseases</i> , 2017 , 76, 341-345	2.4	53
520	Classification of axial SpA based on positive imaging (radiographs and/or MRI of the sacroiliac joints) by local rheumatologists or radiologists versus central trained readers in the DESIR cohort. <i>Annals of the Rheumatic Diseases</i> , 2015 , 74, 2016-21	2.4	53
519	Spinal inflammation in the absence of sacroiliac joint inflammation on magnetic resonance imaging in patients with active nonradiographic axial spondyloarthritis. <i>Arthritis and Rheumatology</i> , 2014 , 66, 667-73	9.5	53
518	Radiographic progression depicted by probability plots: presenting data with optimal use of individual values. <i>Arthritis and Rheumatism</i> , 2004 , 50, 699-706		53
517	Management of psoriatic arthritis in 2016: a comparison of EULAR and GRAPPA recommendations. <i>Nature Reviews Rheumatology</i> , 2016 , 12, 743-750	8.1	52
516	Costs of ankylosing spondylitis in three European countries: the patient's perspective. <i>Annals of the Rheumatic Diseases</i> , 2003 , 62, 741-7	2.4	51
515	Efficacy and safety of non-pharmacological and non-biological pharmacological treatment: a systematic literature review informing the 2016 update of the ASAS/EULAR recommendations for the management of axial spondyloarthritis. <i>RMD Open</i> , 2017 , 3, e000397	5.9	50

514	Points to consider for the treatment of immune-mediated inflammatory diseases with Janus kinase inhibitors: a consensus statement. <i>Annals of the Rheumatic Diseases</i> , 2021 , 80, 71-87	2.4	50
513	Gender-attributable differences in outcome of ankylosing spondylitis: long-term results from the Outcome in Ankylosing Spondylitis International Study. <i>Rheumatology</i> , 2016 , 55, 419-28	3.9	49
512	Evaluation of the validity of the different arms of the ASAS set of criteria for axial spondyloarthritis and description of the different imaging abnormalities suggestive of spondyloarthritis: data from the DESIR cohort. <i>Annals of the Rheumatic Diseases</i> , 2015 , 74, 746-51	2.4	49
511	Low-dose CT detects more progression of bone formation in comparison to conventional radiography in patients with ankylosing spondylitis: results from the SIAS cohort. <i>Annals of the Rheumatic Diseases</i> , 2018 , 77, 293-299	2.4	49
510	MRI findings predict radiographic progression and development of erosions in hand osteoarthritis. <i>Annals of the Rheumatic Diseases</i> , 2016 , 75, 117-23	2.4	48
509	Report from the OMERACT Hand Osteoarthritis Working Group: Set of Core Domains and Preliminary Set of Instruments for Use in Clinical Trials and Observational Studies. <i>Journal of Rheumatology</i> , 2015 , 42, 2190-7	4.1	48
508	Changes in patient characteristics in anti-tumour necrosis factor clinical trials for rheumatoid arthritis: results of an analysis of the literature over the past 16 years. <i>Annals of the Rheumatic Diseases</i> , 2011 , 70, 1631-40	2.4	48
507	Physical function, disease activity, and health-related quality-of-life outcomes after 3 years of adalimumab treatment in patients with ankylosing spondylitis. <i>Arthritis Research and Therapy</i> , 2009 , 11, R124	5.7	48
506	Rate and Predisposing Factors for Sacroiliac Joint Radiographic Progression After a Two-Year Follow-up Period in Recent-Onset Spondyloarthritis. <i>Arthritis and Rheumatology</i> , 2016 , 68, 1904-13	9.5	48
505	DAS28-CRP and DAS28-ESR cut-offs for high disease activity in rheumatoid arthritis are not interchangeable. <i>RMD Open</i> , 2017 , 3, e000382	5.9	47
504	Measurement properties of the ASAS Health Index: results of a global study in patients with axial and peripheral spondyloarthritis. <i>Annals of the Rheumatic Diseases</i> , 2018 , 77, 1311-1317	2.4	47
503	Comparison of features by MRI and radiographs of the interphalangeal finger joints in patients with hand osteoarthritis. <i>Annals of the Rheumatic Diseases</i> , 2012 , 71, 345-50	2.4	47
502	Dual neutralisation of interleukin-17A and interleukin-17F with bimekizumab in patients with active ankylosing spondylitis: results from a 48-week phase IIb, randomised, double-blind, placebo-controlled, dose-ranging study. <i>Annals of the Rheumatic Diseases</i> , 2020 , 79, 595-604	2.4	46
501	Non-steroidal anti-inflammatory drugs (NSAIDs) for axial spondyloarthritis (ankylosing spondylitis and non-radiographic axial spondyloarthritis). <i>The Cochrane Library</i> , 2015 , CD010952	5.2	46
500	Evaluation of the smallest detectable difference in outcome or process variables in ankylosing spondylitis. <i>Arthritis and Rheumatism</i> , 2002 , 47, 582-7		46
499	Efficacy and safety of ixekizumab through 52 weeks in two phase 3, randomised, controlled clinical trials in patients with active radiographic axial spondyloarthritis (COAST-V and COAST-W). <i>Annals of the Rheumatic Diseases</i> , 2020 , 79, 176-185	2.4	46
498	Repair of erosions occurs almost exclusively in damaged joints without swelling. <i>Annals of the Rheumatic Diseases</i> , 2010 , 69, 851-5	2.4	45
497	Characteristics of difficult-to-treat rheumatoid arthritis: results of an international survey. <i>Annals of the Rheumatic Diseases</i> , 2018 , 77, 1705-1709	2.4	45

496	Predictive validity of the ASAS classification criteria for axial and peripheral spondyloarthritis after follow-up in the ASAS cohort: a final analysis. <i>Annals of the Rheumatic Diseases</i> , 2016 , 75, 1034-42	2.4	44
495	A phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group study of 2 dosing regimens of fostamatinib in patients with rheumatoid arthritis with an inadequate response to a tumor necrosis factor- α antagonist. <i>Journal of Rheumatology</i> , 2014 , 41, 2120-8	4.1	43
494	Metrologic properties of ultrasound versus clinical evaluation of synovitis in rheumatoid arthritis: results of a multicenter, randomized study. <i>Arthritis and Rheumatism</i> , 2012 , 64, 1272-82		43
493	Etanercept in the longterm treatment of patients with ankylosing spondylitis. <i>Journal of Rheumatology</i> , 2009 , 36, 1256-64	4.1	43
492	A stratified model for health outcomes in ankylosing spondylitis. <i>Annals of the Rheumatic Diseases</i> , 2011 , 70, 1758-64	2.4	43
491	Effect of certolizumab pegol over ninety-six weeks in patients with axial spondyloarthritis: results from a phase III randomized trial. <i>Arthritis and Rheumatology</i> , 2015 , 67, 668-77	9.5	42
490	Synovitis and radiographic progression in non-erosive and erosive hand osteoarthritis: is erosive hand osteoarthritis a separate inflammatory phenotype?. <i>Osteoarthritis and Cartilage</i> , 2016 , 24, 647-54	6.2	42
489	A Fifty-Two-Week, Randomized, Placebo-Controlled Trial of Certolizumab Pegol in Nonradiographic Axial Spondyloarthritis. <i>Arthritis and Rheumatology</i> , 2019 , 71, 1101-1111	9.5	41
488	Concordance between inflammation at physical examination and on MRI in patients with early arthritis. <i>Annals of the Rheumatic Diseases</i> , 2015 , 74, 506-12	2.4	41
487	How to measure disease activity in axial spondyloarthritis?. <i>Current Opinion in Rheumatology</i> , 2011 , 23, 339-45	5.3	41
486	Reliability and sensitivity to change of the Simple Erosion Narrowing Score compared with the Sharp-van der Heijde method for scoring radiographs in rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2008 , 67, 375-9	2.4	41
485	Selection of a method for scoring radiographs for ankylosing spondylitis clinical trials, by the Assessment in Ankylosing Spondylitis Working Group and OMERACT. <i>Journal of Rheumatology</i> , 2005 , 32, 2048-9	4.1	41
484	Modified stoke ankylosing spondylitis spinal score as an outcome measure to assess the impact of treatment on structural progression in ankylosing spondylitis. <i>Rheumatology</i> , 2019 , 58, 388-400	3.9	40
483	Scoring radiographic progression in ankylosing spondylitis: should we use the modified Stoke Ankylosing Spondylitis Spine Score (mSASSS) or the Radiographic Ankylosing Spondylitis Spinal Score (RASSS)?. <i>Arthritis Research and Therapy</i> , 2013 , 15, R14	5.7	40
482	HLA-B27 and gender independently determine the likelihood of a positive MRI of the sacroiliac joints in patients with early inflammatory back pain: a 2-year MRI follow-up study. <i>Annals of the Rheumatic Diseases</i> , 2011 , 70, 1981-5	2.4	40
481	Magnetic resonance imaging changes of sacroiliac joints in patients with recent-onset inflammatory back pain: inter-reader reliability and prevalence of abnormalities. <i>Arthritis Research and Therapy</i> , 2006 , 8, R11	5.7	40
480	Instruments Measuring Pain, Physical Function, or Patient's Global Assessment in Hand Osteoarthritis: A Systematic Literature Search. <i>Journal of Rheumatology</i> , 2015 , 42, 2118-34	4.1	39
479	ASAS40 and ASDAS clinical responses in the ABILITY-1 clinical trial translate to meaningful improvements in physical function, health-related quality of life and work productivity in patients with non-radiographic axial spondyloarthritis. <i>Rheumatology</i> , 2016 , 55, 80-8	3.9	39

478	Relationship between disease activity indices and their individual components and radiographic progression in RA: a systematic literature review. <i>Rheumatology</i> , 2015 , 54, 994-1007	3.9	39
477	Endorsement of definitions of disease activity states and improvement scores for the Ankylosing Spondylitis Disease Activity Score: results from OMERACT 10. <i>Journal of Rheumatology</i> , 2011 , 38, 1502-6 ^{4.1}		39
476	Scoring of radiographic progression in randomised clinical trials in ankylosing spondylitis: a preference for paired reading order. <i>Annals of the Rheumatic Diseases</i> , 2004 , 63, 1601-4	2.4	39
475	How should treatment effect on spinal radiographic progression in patients with ankylosing spondylitis be measured?. <i>Arthritis and Rheumatism</i> , 2005 , 52, 1979-85		39
474	Ankylosing spondylitis: plenary discussion and results of voting on selection of domains and some specific instruments. <i>Journal of Rheumatology</i> , 1999 , 26, 1003-5	4.1	39
473	Tofacitinib in Combination With Methotrexate in Patients With Rheumatoid Arthritis: Clinical Efficacy, Radiographic, and Safety Outcomes From a Twenty-Four-Month, Phase III Study. <i>Arthritis and Rheumatology</i> , 2019 , 71, 878-891	9.5	38
472	IL-17-producing CD4+ T cells are increased in early, active axial spondyloarthritis including patients without imaging abnormalities. <i>Rheumatology</i> , 2015 , 54, 728-35	3.9	38
471	Characterization of Patients With Ankylosing Spondylitis and Nonradiographic Axial Spondyloarthritis in the US-Based Corrona Registry. <i>Arthritis Care and Research</i> , 2018 , 70, 1661-1670	4.7	38
470	Long-term safety and efficacy of certolizumab pegol in combination with methotrexate in the treatment of rheumatoid arthritis: 5-year results from the RAPID 1 trial and open-label extension. <i>Annals of the Rheumatic Diseases</i> , 2014 , 73, 2094-100	2.4	38
469	Performance of classification criteria for peripheral spondyloarthritis and psoriatic arthritis in the Leiden Early Arthritis cohort. <i>Annals of the Rheumatic Diseases</i> , 2012 , 71, 1366-9	2.4	38
468	Efficacy of cyclo-oxygenase-2 inhibition by etoricoxib and naproxen on the axial manifestations of ankylosing spondylitis in the presence of peripheral arthritis. <i>Annals of the Rheumatic Diseases</i> , 2005 , 64, 1563-7	2.4	38
467	Calculating the ankylosing spondylitis disease activity score if the conventional c-reactive protein level is below the limit of detection or if high-sensitivity c-reactive protein is used: an analysis in the DESIR cohort. <i>Arthritis and Rheumatology</i> , 2015 , 67, 408-13	9.5	37
466	Characteristics associated with the presence and development of extra-articular manifestations in ankylosing spondylitis: 12-year results from OASIS. <i>Rheumatology</i> , 2015 , 54, 633-40	3.9	37
465	Efficacy and safety of certolizumab pegol plus methotrexate in Japanese rheumatoid arthritis patients with an inadequate response to methotrexate: the J-RAPID randomized, placebo-controlled trial. <i>Modern Rheumatology</i> , 2014 , 24, 715-24	3.3	37
464	Adalimumab effectively reduces the signs and symptoms of active ankylosing spondylitis in patients with total spinal ankylosis. <i>Annals of the Rheumatic Diseases</i> , 2008 , 67, 1218-21	2.4	37
463	Radiological scoring methods in ankylosing spondylitis: reliability and sensitivity to change over one year. <i>Journal of Rheumatology</i> , 1999 , 26, 997-1002	4.1	37
462	Classifying Back Pain and Peripheral Joint Complaints in Inflammatory Bowel Disease Patients: A Prospective Longitudinal Follow-up Study. <i>Journal of Crohn's and Colitis</i> , 2016 , 10, 166-75	1.5	36
461	The effect of golimumab therapy on disease activity and health-related quality of life in patients with ankylosing spondylitis: 2-year results of the GO-RAISE trial. <i>Journal of Rheumatology</i> , 2014 , 41, 1095-103 ^{4.1}		36

460	Disease activity is longitudinally related to sacroiliac inflammation on MRI in male patients with axial spondyloarthritis: 2-years of the DESIR cohort. <i>Annals of the Rheumatic Diseases</i> , 2016 , 75, 874-8	2.4	35
459	Pharmacological treatment of psoriatic arthritis: a systematic literature research for the 2019 update of the EULAR recommendations for the management of psoriatic arthritis. <i>Annals of the Rheumatic Diseases</i> , 2020 , 79, 778-786	2.4	35
458	Reappraisal of OMERACT 8 draft validation criteria for a soluble biomarker reflecting structural damage endpoints in rheumatoid arthritis, psoriatic arthritis, and spondyloarthritis: the OMERACT 9 v2 criteria. <i>Journal of Rheumatology</i> , 2009 , 36, 1785-91	4.1	35
457	Performance of the ASAS classification criteria for axial and peripheral spondyloarthritis: a systematic literature review and meta-analysis. <i>Annals of the Rheumatic Diseases</i> , 2017 , 76, 886-890	2.4	34
456	Maintenance of improvement in spinal mobility, physical function and quality of life in patients with ankylosing spondylitis after 5 years in a clinical trial of adalimumab. <i>Rheumatology</i> , 2015 , 54, 1210-9	3.9	34
455	Effect of certolizumab pegol over 96 weeks in patients with psoriatic arthritis with and without prior antitumour necrosis factor exposure. <i>RMD Open</i> , 2015 , 1, e000119	5.9	34
454	The yield of a positive MRI of the spine as imaging criterion in the ASAS classification criteria for axial spondyloarthritis: results from the SPACE and DESIR cohorts. <i>Annals of the Rheumatic Diseases</i> , 2017 , 76, 1731-1736	2.4	34
453	Chronological reading of radiographs in rheumatoid arthritis increases efficiency and does not lead to bias. <i>Annals of the Rheumatic Diseases</i> , 2014 , 73, 391-5	2.4	33
452	Prevalence of degenerative changes of the spine on magnetic resonance images and radiographs in patients aged 16-45 years with chronic back pain of short duration in the Spondyloarthritis Caught Early (SPACE) cohort. <i>Rheumatology</i> , 2016 , 55, 56-65	3.9	32
451	Increasing synovitis and bone marrow lesions are associated with incident joint tenderness in hand osteoarthritis. <i>Annals of the Rheumatic Diseases</i> , 2016 , 75, 702-8	2.4	32
450	Aiming for a simpler early arthritis MRI protocol: can Gd contrast administration be eliminated?. <i>European Radiology</i> , 2015 , 25, 1520-7	8	32
449	How well are the ASAS/OMERACT Core Outcome Sets for Ankylosing Spondylitis implemented in randomized clinical trials? A systematic literature review. <i>Clinical Rheumatology</i> , 2014 , 33, 1313-22	3.9	32
448	Calprotectin as a marker of inflammation in patients with early rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2017 , 76, 2031-2037	2.4	32
447	Filgotinib versus placebo or adalimumab in patients with rheumatoid arthritis and inadequate response to methotrexate: a phase III randomised clinical trial. <i>Annals of the Rheumatic Diseases</i> , 2021 , 80, 848-858	2.4	32
446	Can we use structural lesions seen on MRI of the sacroiliac joints reliably for the classification of patients according to the ASAS axial spondyloarthritis criteria? Data from the DESIR cohort. <i>Annals of the Rheumatic Diseases</i> , 2017 , 76, 392-398	2.4	31
445	Efficacy and safety of certolizumab pegol without methotrexate co-administration in Japanese patients with active rheumatoid arthritis: the HIKARI randomized, placebo-controlled trial. <i>Modern Rheumatology</i> , 2014 , 24, 552-60	3.3	31
444	Reference intervals of spinal mobility measures in normal individuals: the MOBILITY study. <i>Annals of the Rheumatic Diseases</i> , 2015 , 74, 1218-24	2.4	30
443	Discontinuation rates of biologics in patients with rheumatoid arthritis: are TNF inhibitors different from non-TNF inhibitors?. <i>RMD Open</i> , 2015 , 1, e000155	5.9	30

442	The Course of Bone Marrow Edema in Early Undifferentiated Arthritis and Rheumatoid Arthritis: A Longitudinal Magnetic Resonance Imaging Study at Bone Level. <i>Arthritis and Rheumatology</i> , 2016 , 68, 1080-8	9.5	30
441	Proposal for levels of evidence schema for validation of a soluble biomarker reflecting damage endpoints in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis, and recommendations for study design. <i>Journal of Rheumatology</i> , 2009 , 36, 1792-9	4.1	30
440	Erosions versus joint space narrowing in rheumatoid arthritis: what do we know?. <i>Annals of the Rheumatic Diseases</i> , 2011 , 70 Suppl 1, i116-8	2.4	30
439	Radiography as primary outcome in rheumatoid arthritis: acceptable sample sizes for trials with 3 months' follow up. <i>Annals of the Rheumatic Diseases</i> , 2004 , 63, 1413-8	2.4	30
438	An Assessment in SpondyloArthritis International Society (ASAS)-endorsed definition of clinically important worsening in axial spondyloarthritis based on ASDAS. <i>Annals of the Rheumatic Diseases</i> , 2018 , 77, 124-127	2.4	29
437	Aiming for a shorter rheumatoid arthritis MRI protocol: can contrast-enhanced MRI replace T2 for the detection of bone marrow oedema?. <i>European Radiology</i> , 2014 , 24, 2614-22	8	29
436	How do the EQ-5D, SF-6D and the well-being rating scale compare in patients with ankylosing spondylitis?. <i>Annals of the Rheumatic Diseases</i> , 2007 , 66, 771-7	2.4	29
435	Characteristics and burden of disease in patients with radiographic and non-radiographic axial Spondyloarthritis: a comparison by systematic literature review and meta-analysis. <i>RMD Open</i> , 2019 , 5, e001108	5.9	29
434	Association of Comorbidities in Spondyloarthritis With Poor Function, Work Disability, and Quality of Life: Results From the Assessment of SpondyloArthritis International Society Comorbidities in Spondyloarthritis Study. <i>Arthritis Care and Research</i> , 2018 , 70, 1257-1262	4.7	29
433	Preliminary definitions of 'flare' in axial spondyloarthritis, based on pain, BASDAI and ASDAS-CRP: an ASAS initiative. <i>Annals of the Rheumatic Diseases</i> , 2016 , 75, 991-6	2.4	28
432	Updating the OMERACT filter: implications of filter 2.0 to select outcome instruments through assessment of "truth": content, face, and construct validity. <i>Journal of Rheumatology</i> , 2014 , 41, 1000-4	4.1	28
431	Performances of the Assessment of SpondyloArthritis International Society axial spondyloarthritis criteria for diagnostic and classification purposes in patients visiting a rheumatologist because of chronic back pain: results from a multicenter, cross-sectional study. <i>Arthritis Care and Research</i> , 2018 , 70, 1470-81	4.7	28
430	Exploratory analyses of the association of MRI with clinical, laboratory and radiographic findings in patients with rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2011 , 70, 2126-30	2.4	28
429	The safety and efficacy of adding etanercept to methotrexate or methotrexate to etanercept in moderately active rheumatoid arthritis patients previously treated with monotherapy. <i>Annals of the Rheumatic Diseases</i> , 2008 , 67, 182-8	2.4	28
428	Tofacitinib is associated with attainment of the minimally important reduction in axial magnetic resonance imaging inflammation in ankylosing spondylitis patients. <i>Rheumatology</i> , 2018 , 57, 1390-1399	3.9	28
427	Development of EULAR recommendations for the reporting of clinical trial extension studies in rheumatology. <i>Annals of the Rheumatic Diseases</i> , 2015 , 74, 963-9	2.4	27
426	Two years of sarilumab in patients with rheumatoid arthritis and an inadequate response to MTX: safety, efficacy and radiographic outcomes. <i>Rheumatology</i> , 2018 , 57, 1423-1431	3.9	27
425	Do patients with axial spondyloarthritis with radiographic sacroiliitis fulfil both the modified New York criteria and the ASAS axial spondyloarthritis criteria? Results from eight cohorts. <i>Annals of the Rheumatic Diseases</i> , 2019 , 78, 1545-1549	2.4	27

424	Disease activity in ankylosing spondylitis and associations to markers of vascular pathology and traditional cardiovascular disease risk factors: a cross-sectional study. <i>Journal of Rheumatology</i> , 2015 , 42, 645-53	4.1	27
423	Sensitivity and discriminatory ability of the Ankylosing Spondylitis Disease Activity Score in patients treated with etanercept or sulphasalazine in the ASCEND trial. <i>Rheumatology</i> , 2012 , 51, 1894-905	3.9	27
422	Long-term safety of sarilumab in rheumatoid arthritis: an integrated analysis with up to 7 years' follow-up. <i>Rheumatology</i> , 2020 , 59, 292-302	3.9	27
421	Development of the CT Syndesmophyte Score (CTSS) in patients with ankylosing spondylitis: data from the SIAS cohort. <i>Annals of the Rheumatic Diseases</i> , 2018 , 77, 371-377	2.4	27
420	Maintenance of clinical remission in early axial spondyloarthritis following certolizumab pegol dose reduction. <i>Annals of the Rheumatic Diseases</i> , 2020 , 79, 920-928	2.4	26
419	MRI-detected subclinical joint inflammation is associated with radiographic progression. <i>Annals of the Rheumatic Diseases</i> , 2014 , 73, 2034-7	2.4	26
418	When rheumatologists report that they agree with a guideline, does this mean that they practise the guideline in clinical practice? Results of the International Recommendation Implementation Study (IRIS). <i>RMD Open</i> , 2016 , 2, e000221	5.9	26
417	Clinical benefit of 1-year certolizumab pegol (CZP) add-on therapy to methotrexate treatment in patients with early rheumatoid arthritis was observed following CZP discontinuation: 2-year results of the C-OPERA study, a phase III randomised trial. <i>Annals of the Rheumatic Diseases</i> , 2017 , 76, 1348-1356	2.4	25
416	Efficacy and safety of tabalumab, an anti-B-cell-activating factor monoclonal antibody, in patients with rheumatoid arthritis who had an inadequate response to methotrexate therapy: results from a phase III multicentre, randomised, double-blind study. <i>Annals of the Rheumatic Diseases</i> , 2015 , 74, 1567-70	2.4	25
415	CRP and ASDAS are associated with future elevated arterial stiffness, a risk marker of cardiovascular disease, in patients with ankylosing spondylitis: results after 5-year follow-up. <i>Annals of the Rheumatic Diseases</i> , 2015 , 74, 1562-6	2.4	25
414	Improvements in productivity at paid work and within the household, and increased participation in daily activities after 24 weeks of certolizumab pegol treatment of patients with psoriatic arthritis: results of a phase 3 double-blind randomised placebo-controlled study. <i>Annals of the Rheumatic Diseases</i> , 2015 , 74, 44-51	2.4	25
413	Evaluation of the change in structural radiographic sacroiliac joint damage after 2 years of etanercept therapy (EMBARK trial) in comparison to a contemporary control cohort (DESIR cohort) in recent onset axial spondyloarthritis. <i>Annals of the Rheumatic Diseases</i> , 2018 , 77, 221-227	2.4	25
412	4-year results from the RAPID-PsA phase 3 randomised placebo-controlled trial of certolizumab pegol in psoriatic arthritis. <i>RMD Open</i> , 2018 , 4, e000582	5.9	25
411	Work Outcome in Patients With Ankylosing Spondylitis: Results From a 12-Year Followup of an International Study. <i>Arthritis Care and Research</i> , 2016 , 68, 544-52	4.7	25
410	Anti-CD74 antibodies have no diagnostic value in early axial spondyloarthritis: data from the spondyloarthritis caught early (SPACE) cohort. <i>Arthritis Research and Therapy</i> , 2018 , 20, 38	5.7	25
409	Tofacitinib for the treatment of ankylosing spondylitis: a phase III, randomised, double-blind, placebo-controlled study. <i>Annals of the Rheumatic Diseases</i> , 2021 ,	2.4	25
408	The Minimum Clinically Important Improvement and Patient-acceptable Symptom State in the BASDAI and BASFI for Patients with Ankylosing Spondylitis. <i>Journal of Rheumatology</i> , 2016 , 43, 1680-6	4.1	25
407	Illness Perceptions and Outcomes in Patients with Inflammatory Bowel Disease: Is Coping a Mediator?. <i>International Journal of Behavioral Medicine</i> , 2017 , 24, 205-214	2.6	24

406	14-3-3 Autoantibodies: Diagnostic Use in Early Rheumatoid Arthritis. <i>Journal of Rheumatology</i> , 2015 , 42, 1587-94	4.1	24
405	Heterogeneous Disease Trajectories Explain Variable Radiographic, Function and Quality of Life Outcomes in the Canadian Early Arthritis Cohort (CATCH). <i>PLoS ONE</i> , 2015 , 10, e0135327	3.7	24
404	Remission by imaging in rheumatoid arthritis: should this be the ultimate goal?. <i>Annals of the Rheumatic Diseases</i> , 2012 , 71 Suppl 2, i89-92	2.4	24
403	Selecting patients with ankylosing spondylitis for TNF inhibitor therapy: comparison of ASDAS and BASDAI eligibility criteria. <i>Rheumatology</i> , 2012 , 51, 1479-83	3.9	24
402	Impact of Patient's Global Assessment on Achieving Remission in Patients With Rheumatoid Arthritis: A Multinational Study Using the METEOR Database. <i>Arthritis Care and Research</i> , 2019 , 71, 1317-1325	4.7	24
401	Development of ASAS quality standards to improve the quality of health and care services for patients with axial spondyloarthritis. <i>Annals of the Rheumatic Diseases</i> , 2020 , 79, 193-201	2.4	24
400	Evaluation of multiple referral strategies for axial spondyloarthritis in the SPondyloArthritis Caught Early (SPACE) cohort. <i>RMD Open</i> , 2017 , 3, e000389	5.9	23
399	Nonsteroidal Antiinflammatory Drugs for Axial Spondyloarthritis: A Cochrane Review. <i>Journal of Rheumatology</i> , 2016 , 43, 607-17	4.1	23
398	Rates of serious infections, opportunistic infections, inflammatory bowel disease, and malignancies in subjects receiving etanercept vs. controls from clinical trials in ankylosing spondylitis: a pooled analysis. <i>Scandinavian Journal of Rheumatology</i> , 2014 , 43, 49-53	1.9	23
397	Spinal Radiographic Progression in Early Axial Spondyloarthritis: Five-Year Results From the DESIR Cohort. <i>Arthritis Care and Research</i> , 2019 , 71, 1678-1684	4.7	23
396	Relationship between types of radiographic damage and disability in patients with rheumatoid arthritis in the EURIDISS cohort: a longitudinal study. <i>Rheumatology</i> , 2015 , 54, 83-90	3.9	22
395	Is treat-to-target really working in rheumatoid arthritis? a longitudinal analysis of a cohort of patients treated in daily practice (RA BIODAM). <i>Annals of the Rheumatic Diseases</i> , 2020 , 79, 453-459	2.4	22
394	Less educated and older patients have reduced access to biologic DMARDs even in a country with highly developed social welfare (Norway): results from Norwegian cohort study NOR-DMARD. <i>Rheumatology</i> , 2016 , 55, 1217-24	3.9	22
393	Comparison of three enthesitis indices in a multicentre, randomized, placebo-controlled trial of golimumab in ankylosing spondylitis (GO-RAISE). <i>Rheumatology</i> , 2013 , 52, 321-5	3.9	22
392	Filgotinib in combination with methotrexate or as monotherapy versus methotrexate monotherapy in patients with active rheumatoid arthritis and limited or no prior exposure to methotrexate: the phase 3, randomised controlled FINCH 3 trial. <i>Annals of the Rheumatic Diseases</i> , 2021 ,	2.4	22
391	Comparing the disease course of patients with seronegative and seropositive rheumatoid arthritis fulfilling the 2010 ACR/EULAR classification criteria in a treat-to-target setting: 2-year data from the ARCTIC trial. <i>RMD Open</i> , 2018 , 4, e000752	5.9	22
390	Radiographic Progression According to Baseline C-reactive Protein Levels and Other Risk Factors in Psoriatic Arthritis Treated with Tofacitinib or Adalimumab. <i>Journal of Rheumatology</i> , 2019 , 46, 1089-1096	4.1	21
389	What is axial spondyloarthritis? A latent class and transition analysis in the SPACE and DESIR cohorts. <i>Annals of the Rheumatic Diseases</i> , 2020 , 79, 324-331	2.4	21

388	Measuring impairments of functioning and health in patients with axial spondyloarthritis by using the ASAS Health Index and the Environmental Item Set: translation and cross-cultural adaptation into 15 languages. <i>RMD Open</i> , 2016 , 2, e000311	5.9	21
387	A Phase III Study Evaluating Continuation, Tapering, and Withdrawal of Certolizumab Pegol After One Year of Therapy in Patients With Early Rheumatoid Arthritis. <i>Arthritis and Rheumatology</i> , 2017 , 69, 1937-1948	9.5	21
386	Serum biomarkers and changes in clinical/MRI evidence of golimumab-treated patients with ankylosing spondylitis: results of the randomized, placebo-controlled GO-RAISE study. <i>Arthritis Research and Therapy</i> , 2016 , 18, 304	5.7	21
385	Does body mass index (BMI) influence the Ankylosing Spondylitis Disease Activity Score in axial spondyloarthritis?: Data from the SPACE cohort. <i>RMD Open</i> , 2016 , 2, e000283	5.9	20
384	Dual target strategy: a proposal to mitigate the risk of overtreatment and enhance patient satisfaction in rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2019 , 78, e109	2.4	20
383	Aspects of validity of the self-administered comorbidity questionnaire in patients with ankylosing spondylitis. <i>Rheumatology</i> , 2014 , 53, 1054-64	3.9	20
382	Treatment of asymptomatic hyperuricemia for the prevention of gouty arthritis, renal disease, and cardiovascular events: a systematic literature review. <i>Journal of rheumatology Supplement, The</i> , 2014 , 92, 70-4		20
381	Studies on ageing and the severity of radiographic joint damage in rheumatoid arthritis. <i>Arthritis Research and Therapy</i> , 2015 , 17, 222	5.7	20
380	Aspects relevant for functioning in patients with ankylosing spondylitis according to the health professionals: a Delphi study with the ICF as reference. <i>Rheumatology</i> , 2009 , 48, 997-1002	3.9	20
379	Increase in Dickkopf-1 Serum Level in Recent Spondyloarthritis. Data from the DESIR Cohort. <i>PLoS ONE</i> , 2015 , 10, e0134974	3.7	20
378	Effect of Comedication With Conventional Synthetic Disease-Modifying Antirheumatic Drugs on Retention of Tumor Necrosis Factor Inhibitors in Patients With Spondyloarthritis: A Prospective Cohort Study. <i>Arthritis and Rheumatology</i> , 2016 , 68, 2671-2679	9.5	20
377	Radiographic progression in rheumatoid arthritis. <i>Clinical and Experimental Rheumatology</i> , 2005 , 23, S63-82		20
376	Effects of Long-Term Etanercept Treatment on Clinical Outcomes and Objective Signs of Inflammation in Early Nonradiographic Axial Spondyloarthritis: 104-Week Results From a Randomized, Placebo-Controlled Study. <i>Arthritis Care and Research</i> , 2017 , 69, 1590-1598	4.7	19
375	Effect of certolizumab pegol over 96 weeks of treatment on inflammation of the spine and sacroiliac joints, as measured by MRI, and the association between clinical and MRI outcomes in patients with axial spondyloarthritis. <i>RMD Open</i> , 2017 , 3, e000430	5.9	19
374	Magnetic Resonance Imaging in Hand Osteoarthritis: Intraobserver Reliability and Criterion Validity for Clinical and Structural Characteristics. <i>Journal of Rheumatology</i> , 2015 , 42, 1224-30	4.1	19
373	Response to Tumor Necrosis Factor Inhibition in Male and Female Patients with Ankylosing Spondylitis: Data from a Swiss Cohort. <i>Journal of Rheumatology</i> , 2018 , 45, 506-512	4.1	19
372	Five-year follow-up of radiographic sacroiliitis: progression as well as improvement?. <i>Annals of the Rheumatic Diseases</i> , 2016 , 75, 1262-3	2.4	19
371	Certolizumab pegol plus methotrexate 5-year results from the rheumatoid arthritis prevention of structural damage (RAPID) 2 randomized controlled trial and long-term extension in rheumatoid arthritis patients. <i>Arthritis Research and Therapy</i> , 2015 , 17, 245	5.7	19

370	Damage and progression on radiographs in individual joints: data from pivotal randomized controlled trials. <i>Journal of Rheumatology</i> , 2011 , 38, 2018-22	4.1	19
369	Response to: 'Comment on: 'EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2019 update' by Gossec ' by Wei. <i>Annals of the Rheumatic Diseases</i> , 2020 ,	2.4	19
368	Secukinumab provides sustained low rates of radiographic progression in psoriatic arthritis: 52-week results from a phase 3 study, FUTURE 5. <i>Rheumatology</i> , 2020 , 59, 1325-1334	3.9	19
367	Prevalence of Comorbidities and Risk Factors for Comorbidities in Patients with Spondyloarthritis in Latin America: A Comparative Study with the General Population and Data from the ASAS-COMOSPA Study. <i>Journal of Rheumatology</i> , 2018 , 45, 206-212	4.1	19
366	Are gender-specific approaches needed in diagnosing early axial spondyloarthritis? Data from the SPondyloArthritis Caught Early cohort. <i>Arthritis Research and Therapy</i> , 2018 , 20, 218	5.7	19
365	Clinical and ultrasound remission after 6 months of treat-to-target therapy in early rheumatoid arthritis: associations to future good radiographic and physical outcomes. <i>Annals of the Rheumatic Diseases</i> , 2018 , 77, 1421-1425	2.4	19
364	Metric Properties of the SPARCC Score of the Sacroiliac Joints - Data from Baseline, 3-month, and 12-month Followup in the SPACE Cohort. <i>Journal of Rheumatology</i> , 2015 , 42, 1186-93	4.1	18
363	Quality indicators in rheumatoid arthritis: results from the METEOR database. <i>Rheumatology</i> , 2015 , 54, 1630-9	3.9	18
362	Pathophysiology of axial spondyloarthritis: Consensus and controversies. <i>European Journal of Clinical Investigation</i> , 2018 , 48, e12913	4.6	18
361	Common language description of the term rheumatic and musculoskeletal diseases (RMDs) for use in communication with the lay public, healthcare providers and other stakeholders endorsed by the European League Against Rheumatism (EULAR) and the American College of Rheumatology (ACR). <i>Annals of the Rheumatic Diseases</i> , 2018 , 77, 626-633	2.4	18
360	Clinical and MRI remission in patients with nonradiographic axial spondyloarthritis who received long-term open-label adalimumab treatment: 3-year results of the ABILITY-1 trial. <i>Arthritis Research and Therapy</i> , 2018 , 20, 61	5.7	18
359	Structural damage progression in patients with early rheumatoid arthritis treated with methotrexate, baricitinib, or baricitinib plus methotrexate based on clinical response in the phase 3 RA-BEGIN study. <i>Clinical Rheumatology</i> , 2018 , 37, 2381-2390	3.9	18
358	Referral patterns, diagnosis, and disease management of patients with axial spondyloarthritis: results of an international survey. <i>Journal of Clinical Rheumatology</i> , 2014 , 20, 411-7	1.1	18
357	Spinal radiographic progression over 2 years in ankylosing spondylitis patients treated with secukinumab: a historical cohort comparison. <i>Arthritis Research and Therapy</i> , 2019 , 21, 142	5.7	17
356	Are rheumatoid arthritis patients discernible from other early arthritis patients using 1.5T extremity magnetic resonance imaging? a large cross-sectional study. <i>Journal of Rheumatology</i> , 2014 , 41, 1630-7	4.1	17
355	From inhibition of radiographic progression to maintaining structural integrity: a methodological framework for radiographic progression in rheumatoid arthritis and psoriatic arthritis clinical trials. <i>Annals of the Rheumatic Diseases</i> , 2013 , 72, 1113-7	2.4	17
354	Spondyloarthritis: state of the art and future perspectives. <i>Annals of the Rheumatic Diseases</i> , 2010 , 69, 949-54	2.4	17
353	Which aspects of health are most important for patients with spondyloarthritis? A Best Worst Scaling based on the ASAS Health Index. <i>Rheumatology</i> , 2016 , 55, 1771-6	3.9	17

352	Pharmacological and non-pharmacological therapeutic strategies in difficult-to-treat rheumatoid arthritis: a systematic literature review informing the EULAR recommendations for the management of difficult-to-treat rheumatoid arthritis. <i>RMD Open</i> , 2021 , 7,	5.9	17
351	Can disease activity in patients with psoriatic arthritis be adequately assessed by a modified Disease Activity index for Psoriatic Arthritis (DAPSA) based on 28 joints?. <i>Annals of the Rheumatic Diseases</i> , 2018 , 77, 1736-1741	2.4	17
350	Presence of multiple spondyloarthritis (SpA) features is important but not sufficient for a diagnosis of axial spondyloarthritis: data from the SPondyloArthritis Caught Early (SPACE) cohort. <i>Annals of the Rheumatic Diseases</i> , 2017 , 76, 1086-1092	2.4	16
349	How are enthesitis, dactylitis and nail involvement measured and reported in recent clinical trials of psoriatic arthritis? A systematic literature review. <i>Annals of the Rheumatic Diseases</i> , 2018 , 77, 782-783	2.4	16
348	Is the Site of Back Pain Related to the Location of Magnetic Resonance Imaging Lesions in Patients With Chronic Back Pain? Results From the Spondyloarthritis Caught Early Cohort. <i>Arthritis Care and Research</i> , 2017 , 69, 717-723	4.7	16
347	High degree of nonadherence to disease-modifying antirheumatic drugs in patients with rheumatoid arthritis. <i>Journal of Rheumatology</i> , 2015 , 42, 386-90	4.1	16
346	Rheumatoid factor and anti-CCP do not predict progressive joint damage in patients with early rheumatoid arthritis treated with prednisolone: a randomised study. <i>BMJ Open</i> , 2014 , 4, e005246	3	16
345	Is radiographic progression in modern rheumatoid arthritis trials still a robust outcome? Experience from tofacitinib clinical trials. <i>Arthritis Research and Therapy</i> , 2016 , 18, 212	5.7	16
344	Efficacy and Safety of Guselkumab, an Interleukin-23p19-Specific Monoclonal Antibody, Through One Year in Biologic-Naive Patients With Psoriatic Arthritis. <i>Arthritis and Rheumatology</i> , 2021 , 73, 604-616	9.5	16
343	Prevalence of degenerative changes and overlap with spondyloarthritis-associated lesions in the spine of patients from the DESIR cohort. <i>RMD Open</i> , 2018 , 4, e000657	5.9	16
342	The ASAS Health Index (ASAS HI) - a new tool to assess the health status of patients with spondyloarthritis. <i>Clinical and Experimental Rheumatology</i> , 2014 , 32, S-105-8	2.2	16
341	Genetic diagnostic profiling in axial spondyloarthritis: a real world study. <i>Clinical and Experimental Rheumatology</i> , 2017 , 35, 229-233	2.2	16
340	Automated joint space width quantification of hand and wrist joints: a proof of concept study. <i>Clinical and Experimental Rheumatology</i> , 2016 , 34, S34-S39	2.2	16
339	Is a positive family history of spondyloarthritis relevant for diagnosing axial spondyloarthritis once HLA-B27 status is known?. <i>Rheumatology</i> , 2019 , 58, 1649-1654	3.9	15
338	Preliminary Definitions for Sacroiliac Joint Pathologies in the OMERACT Juvenile Idiopathic Arthritis Magnetic Resonance Imaging Score (OMERACT JAMRIS-SIJ). <i>Journal of Rheumatology</i> , 2019 , 46, 1192-1197	4.1	15
337	Induction of sustained remission in early inflammatory arthritis with the combination of infliximab plus methotrexate: the DINORA trial. <i>Arthritis Research and Therapy</i> , 2018 , 20, 174	5.7	15
336	Lifestyle interventions for the treatment of gout: a summary of 2 Cochrane systematic reviews. <i>Journal of rheumatology Supplement, The</i> , 2014 , 92, 26-32		15
335	Comparison of three methods for calculating the Bath Ankylosing Spondylitis Metrology Index in a randomized placebo-controlled study. <i>Arthritis Care and Research</i> , 2012 , 64, 1919-22	4.7	15

334	Testing of the OMERACT 8 draft validation criteria for a soluble biomarker reflecting structural damage in rheumatoid arthritis: a systematic literature search on 5 candidate biomarkers. <i>Journal of Rheumatology</i> , 2009 , 36, 1769-84	4.1	15
333	Predictors of sustained remission in patients with early rheumatoid arthritis treated according to an aggressive treat-to-target protocol. <i>Rheumatology</i> , 2018 , 57, 2022-2031	3.9	14
332	Common Evaluations of Disease Activity in Rheumatoid Arthritis Reach Discordant Classifications across Different Populations. <i>Frontiers in Medicine</i> , 2018 , 5, 40	4.9	14
331	Health-related quality of life in patients with psoriatic and rheumatoid arthritis: data from the prospective multicentre NOR-DMARD study compared with Norwegian general population controls. <i>Annals of the Rheumatic Diseases</i> , 2018 , 77, 1290-1294	2.4	14
330	Accelerometer Quantification of Physical Activity and Activity Patterns in Patients with Ankylosing Spondylitis and Population Controls. <i>Journal of Rheumatology</i> , 2015 , 42, 2369-75	4.1	14
329	Updating the OMERACT filter: discrimination and feasibility. <i>Journal of Rheumatology</i> , 2014 , 41, 1005-104.1	4.1	14
328	Expert agreement confirms that negative changes in hand and foot radiographs are a surrogate for repair in patients with rheumatoid arthritis. <i>Arthritis Research and Therapy</i> , 2007 , 9, R62	5.7	14
327	Efficacy of a tight-control and treat-to-target strategy in axial spondyloarthritis: results of the open-label, pragmatic, cluster-randomised TICOSPA trial. <i>Annals of the Rheumatic Diseases</i> , 2021 , 80, 1436-1444	2.4	14
326	Inequity in biological DMARD prescription for spondyloarthritis across the globe: results from the ASAS-COMOSPA study. <i>Annals of the Rheumatic Diseases</i> , 2018 , 77, 405-411	2.4	14
325	Impact of baseline C-reactive protein levels on the response to secukinumab in ankylosing spondylitis: 3-year pooled data from two phase III studies. <i>RMD Open</i> , 2018 , 4, e000749	5.9	14
324	Effects of baricitinib on radiographic progression of structural joint damage at 1 year in patients with rheumatoid arthritis and an inadequate response to conventional synthetic disease-modifying antirheumatic drugs. <i>RMD Open</i> , 2018 , 4, e000662	5.9	14
323	Efficacy of guselkumab on axial involvement in patients with active psoriatic arthritis and sacroiliitis: a post-hoc analysis of the phase 3 DISCOVER-1 and DISCOVER-2 studies. <i>Lancet Rheumatology, The</i> , 2021 , 3, e715-e723	14.2	14
322	The effect of tumour necrosis factor inhibitors on radiographic progression in axial spondyloarthritis: a systematic literature review. <i>Rheumatology</i> , 2019 , 58, 1907-1922	3.9	13
321	Assessing structural damage progression in psoriatic arthritis and its role as an outcome in research. <i>Arthritis Research and Therapy</i> , 2020 , 22, 18	5.7	13
320	The Impact of Illness Perceptions and Coping on the Association Between Back Pain and Health Outcomes in Patients Suspected of Having Axial Spondyloarthritis: Data From the SPondyloArthritis Caught Early Cohort. <i>Arthritis Care and Research</i> , 2018 , 70, 1829-1839	4.7	13
319	Hierarchy of Impairment of Spinal Mobility Measures in Ankylosing Spondylitis: Twelve-Year Data. <i>Arthritis Care and Research</i> , 2015 , 67, 1571-7	4.7	13
318	Inhibition of radiographic progression with combination etanercept and methotrexate in patients with moderately active rheumatoid arthritis previously treated with monotherapy. <i>Annals of the Rheumatic Diseases</i> , 2009 , 68, 1113-8	2.4	13
317	LB0001 EFFICACY AND SAFETY OF FILGOTINIB FOR PATIENTS WITH RHEUMATOID ARTHRITIS WITH INADEQUATE RESPONSE TO METHOTREXATE: FINCH1 PRIMARY OUTCOME RESULTS 2019 ,		13

316	Long-term safety and efficacy of sarilumab plus methotrexate on disease activity, physical function and radiographic progression: 5 years of sarilumab plus methotrexate treatment. <i>RMD Open</i> , 2019 , 5, e000887	5.9	13
315	Is it Useful to Repeat Magnetic Resonance Imaging of the Sacroiliac Joints After Three Months or One Year in the Diagnosis of Patients With Chronic Back Pain and Suspected Axial Spondyloarthritis?. <i>Arthritis and Rheumatology</i> , 2019 , 71, 382-391	9.5	13
314	Data-driven definitions for active and structural MRI lesions in the sacroiliac joint in spondyloarthritis and their predictive utility. <i>Rheumatology</i> , 2021 , 60, 4778-4789	3.9	13
313	Effect of Glucocorticoids on the Clinical and Radiographic Efficacy of Tofacitinib in Patients with Rheumatoid Arthritis: A Posthoc Analysis of Data from 6 Phase III Studies. <i>Journal of Rheumatology</i> , 2018 , 45, 177-187	4.1	13
312	Ixekizumab treatment of biologic-naïve patients with active psoriatic arthritis: 3-year results from a phase III clinical trial (SPIRIT-P1). <i>Rheumatology</i> , 2020 , 59, 2774-2784	3.9	12
311	Common Language Description of the Term Rheumatic and Musculoskeletal Diseases (RMDs) for Use in Communication With the Lay Public, Healthcare Providers, and Other Stakeholders Endorsed by the European League Against Rheumatism (EULAR) and the American College of Rheumatology (ACR). <i>Arthritis and Rheumatology</i> , 2018 , 70, 664-667	9.5	12
310	The Impact of Ultrasound on the Use and Efficacy of Intraarticular Glucocorticoid Injections in Early Rheumatoid Arthritis: Secondary Analyses From a Randomized Trial Examining the Benefit of Ultrasound in a Clinical Tight Control Regimen. <i>Arthritis and Rheumatology</i> , 2018 , 70, 1192-1199	9.5	12
309	Existing joint erosions increase the risk of joint space narrowing independently of clinical synovitis in patients with early rheumatoid arthritis. <i>Arthritis Research and Therapy</i> , 2015 , 17, 133	5.7	12
308	Cardiovascular and selected comorbidities in early arthritis and early spondyloarthritis, a comparative study: results from the ESPOIR and DESIR cohorts. <i>RMD Open</i> , 2015 , 1, e000128	5.9	12
307	FRI0335 THE EFFECT OF TOFACITINIB ON RESIDUAL PAIN IN PATIENTS WITH PSORIATIC ARTHRITIS. <i>Annals of the Rheumatic Diseases</i> , 2020 , 79, 760-761	2.4	12
306	Efficacy of denosumab with regard to bone destruction in prognostic subgroups of Japanese rheumatoid arthritis patients from the phase II DRIVE study. <i>Rheumatology</i> , 2019 , 58, 997-1005	3.9	12
305	Individual-level and country-level socioeconomic determinants of disease outcomes in SpA: multinational, cross-sectional study (ASAS-COMOSPA). <i>Annals of the Rheumatic Diseases</i> , 2019 , 78, 486-493	2.4	11
304	"Big Data" in Rheumatology: Intelligent Data Modeling Improves the Quality of Imaging Data. <i>Rheumatic Disease Clinics of North America</i> , 2018 , 44, 307-315	2.4	11
303	Analysis and performance of various classification criteria sets in a Colombian cohort of patients with spondyloarthritis. <i>Clinical Rheumatology</i> , 2016 , 35, 1759-67	3.9	11
302	Work participation in spondyloarthritis across countries: analysis from the ASAS-COMOSPA study. <i>Annals of the Rheumatic Diseases</i> , 2018 , 77, 1303-1310	2.4	11
301	The performance of different classification criteria sets for spondyloarthritis in the worldwide ASAS-COMOSPA study. <i>Arthritis Research and Therapy</i> , 2017 , 19, 96	5.7	11
300	Analysis of integrated radiographic data from two long-term, open-label extension studies of adalimumab for the treatment of rheumatoid arthritis. <i>Arthritis Care and Research</i> , 2015 , 67, 180-6	4.7	11
299	Assessment of sacroiliitis by radiographs and MRI: where are we now?. <i>Current Opinion in Rheumatology</i> , 2014 , 26, 384-8	5.3	11

298	Development and Validation of a Short Form of the Social Role Participation Questionnaire in Patients with Ankylosing Spondylitis. <i>Journal of Rheumatology</i> , 2016 , 43, 1386-92	4.1	11
297	Prevalence and distribution of peripheral musculoskeletal manifestations in spondyloarthritis including psoriatic arthritis: results of the worldwide, cross-sectional ASAS-PerSpA study. <i>RMD Open</i> , 2021 , 7,	5.9	11
296	First step in the development of an ultrasound joint inflammation score for rheumatoid arthritis using a data-driven approach. <i>Annals of the Rheumatic Diseases</i> , 2016 , 75, 1444-51	2.4	10
295	Clinical Characteristics of Patients with Spondyloarthritis in Japan in Comparison with Other Regions of the World. <i>Journal of Rheumatology</i> , 2019 , 46, 896-903	4.1	10
294	LB0001 Baricitinib, an Oral Janus Kinase (JAK)1/JAK2 Inhibitor, in Patients with Active Rheumatoid Arthritis (RA) and An Inadequate Response to CDMARD Therapy: Results of the Phase 3 RA-Build Study. <i>Annals of the Rheumatic Diseases</i> , 2015 , 74, 79.2-79	2.4	10
293	Pragmatic randomised controlled trial of very early etanercept and MTX versus MTX with delayed etanercept in RA: the VEDERA trial. <i>Annals of the Rheumatic Diseases</i> , 2020 , 79, 464-471	2.4	10
292	Social Role Participation and Satisfaction With Life: A Study Among Patients With Ankylosing Spondylitis and Population Controls. <i>Arthritis Care and Research</i> , 2018 , 70, 600-607	4.7	10
291	Social Role Participation in Patients With Ankylosing Spondylitis: A Cross-Sectional Comparison With Population Controls. <i>Arthritis Care and Research</i> , 2016 , 68, 1899-1905	4.7	10
290	Measurement error in the assessment of radiographic progression in rheumatoid arthritis (RA) clinical trials: the smallest detectable change (SDC) revisited. <i>Annals of the Rheumatic Diseases</i> , 2014 , 73, 1067-70	2.4	10
289	Is the current ASAS expert definition of a positive family history useful in identifying axial spondyloarthritis? Results from the SPACE and DESIR cohorts. <i>Arthritis Research and Therapy</i> , 2017 , 19, 118	5.7	10
288	Early Disease Activity or Clinical Response as Predictors of Long-Term Outcomes With Certolizumab Pegol in Axial Spondyloarthritis or Psoriatic Arthritis. <i>Arthritis Care and Research</i> , 2017 , 69, 1030-1039	4.7	10
287	Twenty-eight-week results from the REALISTIC phase IIIb randomized trial: efficacy, safety and predictability of response to certolizumab pegol in a diverse rheumatoid arthritis population. <i>Arthritis Research and Therapy</i> , 2015 , 17, 325	5.7	10
286	Can we improve the performance and reporting of investigator-initiated clinical trials? Rheumatoid arthritis as an example. <i>Annals of the Rheumatic Diseases</i> , 2014 , 73, 1755-60	2.4	10
285	Justification for including MRI as a tool in the diagnosis of axial SpA. <i>Nature Reviews Rheumatology</i> , 2010 , 6, 670-2	8.1	10
284	Is avoidant coping independent of disease status and stable over time in patients with ankylosing spondylitis?. <i>Annals of the Rheumatic Diseases</i> , 2004 , 63, 1264-8	2.4	10
283	Points to consider for the treatment of immune-mediated inflammatory diseases with Janus kinase inhibitors: a systematic literature research. <i>RMD Open</i> , 2020 , 6,	5.9	10
282	Fluctuations in patient reported disease activity, pain and global being in patients with ankylosing spondylitis. <i>Rheumatology</i> , 2016 , 55, 2014-2022	3.9	10
281	Revisiting the use of remission criteria for rheumatoid arthritis by excluding patient global assessment: an individual meta-analysis of 5792 patients. <i>Annals of the Rheumatic Diseases</i> , 2020 ,	2.4	10

280	EULAR recommendations for the reporting of ultrasound studies in rheumatic and musculoskeletal diseases (RMDs). <i>Annals of the Rheumatic Diseases</i> , 2021 , 80, 840-847	2.4	10
279	Do extra-articular manifestations influence outcome in ankylosing spondylitis? 12-year results from OASIS. <i>Clinical and Experimental Rheumatology</i> , 2016 , 34, 214-21	2.2	10
278	Conventional versus ultrasound treat to target: no difference in magnetic resonance imaging inflammation or joint damage over 2 years in early rheumatoid arthritis. <i>Rheumatology</i> , 2020 , 59, 2550-2555	3.9	9
277	Impact of replacing radiographic sacroiliitis by magnetic resonance imaging structural lesions on the classification of patients with axial spondyloarthritis. <i>Rheumatology</i> , 2018 , 57, 1186-1193	3.9	9
276	Low specificity but high sensitivity of inflammatory back pain criteria in rheumatology settings in Europe: confirmation of findings from a German cohort study. <i>Annals of the Rheumatic Diseases</i> , 2019 , 78, 1605-1606	2.4	9
275	Treatment of gout patients with impairment of renal function: a systematic literature review. <i>Journal of rheumatology Supplement, The</i> , 2014 , 92, 48-54		9
274	Disease activity decrease is associated with improvement in work productivity over 1 year in early axial spondyloarthritis (SPondyloArthritis Caught Early cohort). <i>Rheumatology</i> , 2017 , 56, 2222-2228	3.9	9
273	Cerebral magnetic resonance imaging in quiescent Crohn's disease patients with fatigue. <i>World Journal of Gastroenterology</i> , 2017 , 23, 1018-1029	5.6	9
272	Two different invitation approaches for consecutive rounds of a Delphi survey led to comparable final outcome. <i>Journal of Clinical Epidemiology</i> , 2021 , 129, 31-39	5.7	9
271	Efficacy and safety of selective TYK2 inhibitor, deucravacitinib, in a phase II trial in psoriatic arthritis.. <i>Annals of the Rheumatic Diseases</i> , 2022 ,	2.4	9
270	Low rates of radiographic progression of structural joint damage over 2 years of baricitinib treatment in patients with rheumatoid arthritis. <i>RMD Open</i> , 2019 , 5, e000898	5.9	8
269	Should radiographic progression still be used as outcome in RA?. <i>Clinical Immunology</i> , 2018 , 186, 79-81	9	8
268	What is the reliability of non-trained investigators in recognising structural MRI lesions of sacroiliac joints in patients with recent inflammatory back pain? Results of the DESIR cohort. <i>RMD Open</i> , 2016 , 2, e000303	5.9	8
267	Performance of the Michigan Hand Outcomes Questionnaire in hand osteoarthritis. <i>Osteoarthritis and Cartilage</i> , 2018 , 26, 1627-1635	6.2	8
266	Preventing attacks of acute gout when introducing urate-lowering therapy: a systematic literature review. <i>Journal of rheumatology Supplement, The</i> , 2014 , 92, 42-7		8
265	Tumor Necrosis Factor Inhibitors Reduce Spinal Radiographic Progression in Patients With Radiographic Axial Spondyloarthritis: A Longitudinal Analysis From the Alberta Prospective Cohort. <i>Arthritis and Rheumatology</i> , 2021 , 73, 1211-1219	9.5	8
264	Report from the Hand Osteoarthritis Working Group at OMERACT 2018: Update on Core Instrument Set Development. <i>Journal of Rheumatology</i> , 2019 , 46, 1183-1187	4.1	8
263	Tumor Necrosis Factor Inhibitor Discontinuation in Patients with Ankylosing Spondylitis: An Observational Study From the US-Based Corrona Registry. <i>Rheumatology and Therapy</i> , 2018 , 5, 537-550	4.4	8

262	Imaging of the sacroiliac joints is important for diagnosing early axial spondyloarthritis but not all-decisive. <i>Rheumatology</i> , 2018 , 57, 1173-1179	3.9	7
261	Validity, reliability, responsiveness and feasibility of four hand mobility measures in hand osteoarthritis. <i>Rheumatology</i> , 2018 , 57, 525-532	3.9	7
260	In Early Axial Spondyloarthritis, Increasing Disease Activity Is Associated with Worsening of Health-related Quality of Life over Time. <i>Journal of Rheumatology</i> , 2018 , 45, 779-784	4.1	7
259	Linear extrapolation of missing radiographic change scores in clinical trials does not spuriously overestimate group radiographic changes in rheumatoid arthritis. <i>Rheumatology</i> , 2016 , 55, 1295-300	3.9	7
258	Signal intensity loss of the intervertebral discs in the cervical spine of young patients on fluid sensitive sequences. <i>Skeletal Radiology</i> , 2016 , 45, 375-81	2.7	7
257	Urate-lowering therapy for the management of gout: a summary of 2 Cochrane reviews. <i>Journal of rheumatology Supplement, The</i> , 2014 , 92, 33-41		7
256	Bone marrow edema on magnetic resonance imaging (MRI) of the sacroiliac joints is associated with development of fatty lesions on MRI over a 1-year interval in patients with early inflammatory low back pain: a 2-year followup study. <i>Journal of Rheumatology</i> , 2014 , 41, 1088-94	4.1	7
255	Uveitis is associated with hypertension and atherosclerosis in patients with ankylosing spondylitis: a cross-sectional study. <i>Seminars in Arthritis and Rheumatism</i> , 2014 , 44, 309-13	5.3	7
254	THU0275 Sustained efficacy of adalimumab in patients with non-radiographic axial spondyloarthritis: Week 68 results from ability 1. <i>Annals of the Rheumatic Diseases</i> , 2013 , 71, 248.1-248	2.4	7
253	Axial spondyloarthritis. <i>Annals of the Rheumatic Diseases</i> , 2021 , 80, 1511-1521	2.4	7
252	Effect of Half-Dose vs Stable-Dose Conventional Synthetic Disease-Modifying Antirheumatic Drugs on Disease Flares in Patients With Rheumatoid Arthritis in Remission: The ARCTIC REWIND Randomized Clinical Trial. <i>JAMA - Journal of the American Medical Association</i> , 2021 , 325, 1755-1764	27.4	7
251	Development of a feasible and responsive ultrasound inflammation score for rheumatoid arthritis through a data-driven approach. <i>RMD Open</i> , 2016 , 2, e000325	5.9	7
250	Is active sacroiliitis on MRI associated with radiographic damage in axial spondyloarthritis? Real-life data from the ASAS and DESIR cohorts. <i>Rheumatology</i> , 2019 , 58, 798-802	3.9	7
249	Adherence to Treat-to-target Management in Rheumatoid Arthritis and Associated Factors: Data from the International RA BIODAM Cohort. <i>Journal of Rheumatology</i> , 2020 , 47, 809-819	4.1	7
248	Value of MRI and ultrasound for prediction of therapeutic response and erosive progression in patients with early rheumatoid arthritis managed by an aggressive treat-to-target strategy. <i>RMD Open</i> , 2021 , 7,	5.9	7
247	Uncovering the heterogeneity of disease impact in axial spondyloarthritis: bivariate trajectories of disease activity and quality of life. <i>RMD Open</i> , 2018 , 4, e000755	5.9	7
246	Sick leave and its predictors in ankylosing spondylitis: long-term results from the Outcome in Ankylosing Spondylitis International Study. <i>RMD Open</i> , 2018 , 4, e000766	5.9	7
245	Long-Term Radiographic and Patient-Reported Outcomes in Patients with Rheumatoid Arthritis Treated with Tofacitinib: ORAL Start and ORAL Scan Post-hoc Analyses. <i>Rheumatology and Therapy</i> , 2018 , 5, 341-353	4.4	7

244	Frequency of Impaired Spinal Mobility in Patients with Chronic Back Pain Compared to Patients with Early Axial Spondyloarthritis. <i>Journal of Rheumatology</i> , 2018 , 45, 1643-1650	4.1	7
243	Prevalence and clinical significance of lumbosacral transitional vertebra (LSTV) in a young back pain population with suspected axial spondyloarthritis: results of the SPondyloArthritis Caught Early (SPACE) cohort. <i>Skeletal Radiology</i> , 2017 , 46, 633-639	2.7	6
242	Percentage of progressors in imaging: can we ignore regressors?. <i>RMD Open</i> , 2019 , 5, e000848	5.9	6
241	Measuring spinal mobility in early axial spondyloarthritis: does it matter?. <i>Rheumatology</i> , 2019 , 58, 1597-1606	3.6	6
240	5-year follow-up of spinal and sacroiliac MRI abnormalities in early axial spondyloarthritis: data from the DESIR cohort. <i>RMD Open</i> , 2020 , 6,	5.9	6
239	Facet joint ankylosis in r-axSpA: detection and 2-year progression on whole spine low-dose CT and comparison with syndesmophyte progression. <i>Rheumatology</i> , 2020 , 59, 3776-3783	3.9	6
238	Induction of Sustained Clinical Remission in Early Axial Spondyloarthritis Following Certolizumab Pegol Treatment: 48-Week Outcomes from C-OPTIMISE. <i>Rheumatology and Therapy</i> , 2020 , 7, 581-599	4.4	6
237	Social Role Participation Questionnaire for patients with ankylosing spondylitis: translation into Dutch, reliability and construct validity. <i>RMD Open</i> , 2016 , 2, e000177	5.9	6
236	Certolizumab Pegol Efficacy Across Methotrexate Regimens: A Pre-Specified Analysis of Two Phase III Trials. <i>Arthritis Care and Research</i> , 2016 , 68, 299-307	4.7	6
235	Do ethnicity, degree of family relationship, and the spondyloarthritis subtype in affected relatives influence the association between a positive family history for spondyloarthritis and HLA-B27 carriership? Results from the worldwide ASAS cohort. <i>Arthritis Research and Therapy</i> , 2018 , 20, 166	5.7	6
234	Interventions for tophi in gout: a Cochrane systematic literature review. <i>Journal of rheumatology Supplement, The</i> , 2014 , 92, 63-9		6
233	Why CAPS criteria are not diagnostic criteria?. <i>Annals of the Rheumatic Diseases</i> , 2017 , 76, e7	2.4	6
232	When to adjust therapy in patients with rheumatoid arthritis after initiation of etanercept plus methotrexate or methotrexate alone: findings from a randomized study (COMET). <i>Journal of Rheumatology</i> , 2014 , 41, 1922-34	4.1	6
231	Association of the different types of radiographic damage with physical function in patients with rheumatoid arthritis: analysis of the RAPID trials. <i>RMD Open</i> , 2016 , 2, e000219	5.9	6
230	Improvements in workplace and household productivity with certolizumab pegol treatment in axial spondyloarthritis: results to week 96 of a phase III study. <i>RMD Open</i> , 2018 , 4, e000659	5.9	6
229	Response to: 'Correspondence on 'EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2019 update' by Fallon. <i>Annals of the Rheumatic Diseases</i> , 2020 ,	2.4	6
228	Employment and the role of personal factors among patients with ankylosing spondylitis: a Dutch cross-sectional case-control study. <i>RMD Open</i> , 2018 , 4, e000680	5.9	6
227	Validity of the rheumatoid arthritis MRI score applied to the forefeet using the OMERACT filter: a systematic literature review. <i>RMD Open</i> , 2018 , 4, e000796	5.9	6

226	The ASAS-OMERACT core domain set for axial spondyloarthritis. <i>Seminars in Arthritis and Rheumatism</i> , 2021 ,	5.3	6
225	EULAR points to consider for the management of difficult-to-treat rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2021 ,	2.4	6
224	Tofacitinib in combination with methotrexate in patients with rheumatoid arthritis: patient-reported outcomes from the 24-month Phase 3 ORAL Scan study. <i>Clinical and Experimental Rheumatology</i> , 2020 , 38, 848-857	2.2	6
223	Automatic Quantification of Radiographic Wrist Joint Space Width of Patients With Rheumatoid Arthritis. <i>IEEE Transactions on Biomedical Engineering</i> , 2017 , 64, 2695-2703	5	5
222	Do Smoking and Socioeconomic Factors Influence Imaging Outcomes in Axial Spondyloarthritis? Five-Year Data From the DESIR Cohort. <i>Arthritis and Rheumatology</i> , 2020 , 72, 1855-1862	9.5	5
221	Dose reduction and withdrawal strategy for TNF-inhibitors in psoriatic arthritis and axial spondyloarthritis: design of a pragmatic open-label, randomised, non-inferiority trial. <i>Trials</i> , 2020 , 21, 90	2.8	5
220	Inhibition of spinal bone formation in AS: 10 years after comparing adalimumab to OASIS. <i>Arthritis Research and Therapy</i> , 2019 , 21, 225	5.7	5
219	Role of erosions typical of rheumatoid arthritis in the 2010 ACR/EULAR rheumatoid arthritis classification criteria: results from a very early arthritis cohort. <i>Annals of the Rheumatic Diseases</i> , 2017 , 76, 1911-1914	2.4	5
218	Assessment of typical SpA lesions on MRI of the spine: do local readers and central readers agree in the DESIR-cohort at baseline?. <i>Clinical Rheumatology</i> , 2017 , 36, 1551-1559	3.9	5
217	Treatment-resistant synovitis and radiographic progression are increased in elderly-onset rheumatoid arthritis patients: findings from a prospective observational longitudinal early arthritis cohort study. <i>Seminars in Arthritis and Rheumatism</i> , 2020 , 50, 735-743	5.3	5
216	Are Additional Tests Needed to Rule Out Axial Spondyloarthritis in Patients Ages 16-45 Years With Short-Duration Chronic Back Pain and Maximally One Spondyloarthritis Feature?. <i>Arthritis Care and Research</i> , 2016 , 68, 1726-1730	4.7	5
215	Reliability of mSASSS scoring in everyday practice in DESIR-cohort study centres: cross-sectional study of agreement with trained readers. <i>Annals of the Rheumatic Diseases</i> , 2016 , 75, 2213-2214	2.4	5
214	OP0002 Tofacitinib in Patients with Ankylosing Spondylitis: A Phase 2, 16-Week, Randomised, Placebo-Controlled, Dose-Ranging Study. <i>Annals of the Rheumatic Diseases</i> , 2016 , 75, 52.2-53	2.4	5
213	LB0003 EFFICACY AND SAFETY OF FILGOTINIB FOR PATIENTS WITH RHEUMATOID ARTHRITIS NAÏVE TO METHOTREXATE THERAPY: FINCH3 PRIMARY OUTCOME RESULTS 2019 ,		5
212	Development and validation of an alternative ankylosing spondylitis disease activity score when patient global assessment is unavailable. <i>Rheumatology</i> , 2021 , 60, 638-648	3.9	5
211	Disease activity is associated with spinal radiographic progression in axial spondyloarthritis independently of exposure to tumour necrosis factor inhibitors. <i>Rheumatology</i> , 2021 , 60, 461-462	3.9	5
210	Validation and reliability of translation of the ASAS Health Index in a Colombian Spanish-speaking population with spondyloarthritis. <i>Clinical Rheumatology</i> , 2018 , 37, 3063-3068	3.9	5
209	Which scoring method depicts spinal radiographic damage in early axial spondyloarthritis best? Five-year results from the DESIR cohort. <i>Rheumatology</i> , 2018 , 57, 1991-2000	3.9	5

208	Flare in axial spondyloarthritis: investigation of meaningful changes in symptomatic outcome measures. <i>Clinical and Experimental Rheumatology</i> , 2017 , 35, 209-213	2.2	5
207	The impact of patient global assessment in the definition of remission as a predictor of long-term radiographic damage in patients with rheumatoid arthritis: protocol for an individual patient data meta-analysis. <i>Acta Reumatologica Portuguesa</i> , 2018 , 43, 52-60	0.7	5
206	Response to: '2016 update of the EULAR recommendations for the management of rheumatoid arthritis: no utopia for patients in low/middle-income countries?' by Misra. <i>Annals of the Rheumatic Diseases</i> , 2017 , 76, e48	2.4	4
205	Achieving comprehensive disease control in patients with early and established rheumatoid arthritis treated with adalimumab plus methotrexate versus methotrexate alone. <i>RMD Open</i> , 2017 , 3, e000445	5.9	4
204	Reliability of Magnetic Resonance Imaging (MRI) Scoring of the Metatarsophalangeal Joints of the Foot according to the Rheumatoid Arthritis MRI Score. <i>Journal of Rheumatology</i> , 2020 , 47, 1165-1173	4.1	4
203	Central reader evaluation of MRI scans of the sacroiliac joints from the ASAS classification cohort: discrepancies with local readers and impact on the performance of the ASAS criteria. <i>Annals of the Rheumatic Diseases</i> , 2020 , 79, 935-942	2.4	4
202	Development of classification criteria for hand osteoarthritis: comparative analyses of persons with and without hand osteoarthritis. <i>RMD Open</i> , 2020 , 6,	5.9	4
201	The influence of discrepant imaging judgements on the classification of axial spondyloarthritis is limited: a replication in the SpondyloArthritis Caught Early (SPACE) cohort. <i>Annals of the Rheumatic Diseases</i> , 2018 , 77, e1	2.4	4
200	SAT0222 Effects of Tofacitinib on MRI Endpoints in Methotrexate-Naive Early Rheumatoid Arthritis: A Phase 2 MRI Study with Semi-Quantitative and Quantitative Endpoints. <i>Annals of the Rheumatic Diseases</i> , 2015 , 74, 738-738	2.4	4
199	Spondyloarthritis features forecasting the presence of HLA-B27 or sacroiliitis on magnetic resonance imaging in patients with suspected axial spondyloarthritis: results from a cross-sectional study in the ESPeranza Cohort. <i>Arthritis Research and Therapy</i> , 2015 , 17, 265	5.7	4
198	Comment on: 'comparison of Tripterygium wilfordii Hook F with methotrexate in the treatment of active rheumatoid arthritis (TRIFRA): a randomised, controlled clinical trial' by Qian-wen et al. <i>Annals of the Rheumatic Diseases</i> , 2014 , 73, e62	2.4	4
197	OP0106 Effect of Certolizumab Pegol on Signs and Symptoms of Axial Spondyloarthritis, Including Ankylosing Spondylitis and Non-Radiographic Axial Spondyloarthritis: 24-Week Results of Rapid-Axspa Study. <i>Annals of the Rheumatic Diseases</i> , 2013 , 72, A86.2-A87	2.4	4
196	Long-term Efficacy and Safety of Guselkumab, a Monoclonal Antibody Specific to the p19 Subunit of Interleukin-23, Through 2 Years: Results from a Phase 3, Randomized, Double-blind, Placebo-controlled Study Conducted in Biologic-naïve Patients with Active Psoriatic Arthritis. <i>Arthritis and Rheumatology</i> , 2021 ,	9.5	4
195	Relationship between disease activity status or clinical response and patient-reported outcomes in patients with non-radiographic axial spondyloarthritis: 104-week results from the randomized controlled EMBARK study. <i>Health and Quality of Life Outcomes</i> , 2020 , 18, 4	3	4
194	Ixekizumab Improves Functioning and Health in the Treatment of Active Non-Radiographic Axial Spondyloarthritis: 52-Week Results, COAST-X Trial. <i>Arthritis Care and Research</i> , 2020 ,	4.7	4
193	Identifying the preferable rheumatoid arthritis subgroups for intervention with the anti-RANKL antibody denosumab to reduce progression of joint destruction. <i>RMD Open</i> , 2020 , 6,	5.9	4
192	Measuring Outcomes in Axial Spondyloarthritis. <i>Arthritis Care and Research</i> , 2020 , 72 Suppl 10, 47-71	4.7	4
191	Ixekizumab Improves Functioning and Health in the Treatment of Radiographic Axial Spondyloarthritis: Week 52 Results from 2 Pivotal Studies. <i>Journal of Rheumatology</i> , 2021 , 48, 188-197	4.1	4

190	Diagnostic issues in difficult-to-treat rheumatoid arthritis: a systematic literature review informing the EULAR recommendations for the management of difficult-to-treat rheumatoid arthritis. <i>RMD Open</i> , 2021 , 7,	5.9	4
189	A systematic comparison of rheumatoid arthritis and ankylosing spondylitis: structural outcomes. <i>Clinical and Experimental Rheumatology</i> , 2009 , 27, S102-7	2.2	4
188	Discriminant Capacity of Clinical Efficacy and Nonsteroidal Antiinflammatory Drug-sparing Endpoints, Alone or in Combination, in Axial Spondyloarthritis. <i>Journal of Rheumatology</i> , 2015 , 42, 2361-8	4.1	3
187	Are conventional radiographs still of value?. <i>Current Opinion in Rheumatology</i> , 2016 , 28, 310-5	5.3	3
186	Associations Between Cardiorespiratory Fitness and Arterial Stiffness in Ankylosing Spondylitis: A Cross-sectional Study. <i>Journal of Rheumatology</i> , 2018 , 45, 1522-1525	4.1	3
185	OP0216 Efficacy and safety of tofacitinib, an oral janus kinase inhibitor, or adalimumab in patients with active psoriatic arthritis and an inadequate response to conventional synthetic disease-modifying antirheumatic drugs (CSDMARDs): a randomised, placebo-controlled, phase 3 trial 2017 ,		3
184	Is there a relationship between spondyloarthritis and periodontitis? A case-control study. <i>RMD Open</i> , 2017 , 3, e000547	5.9	3
183	FRI0278 The First Early Rheumatoid Arthritis, Certolizumab Pegol, Multicenter, Double-Blind, Randomized, Parallel-Group Study: C-Opera, in Patients Fulfilling the 2010 Acr/Eular Classification Criteria, Demonstrates Inhibition of Joint Damage Progression. <i>Annals of the Rheumatic Diseases</i> , 2014 , 73, 1841-184	2.4	3
182	OP0022 Abatacept sc versus adalimumab on background methotrexate in RA: One year results from the ample study. <i>Annals of the Rheumatic Diseases</i> , 2013 , 71, 60.1-60	2.4	3
181	Spinal Radiographic Progression and Predictors of Progression in Patients With Radiographic Axial Spondyloarthritis Receiving Ixekizumab Over 2 Years. <i>Journal of Rheumatology</i> , 2021 ,	4.1	3
180	The impact of autoantibodies against citrullinated, carbamylated, and acetylated peptides on radiographic progression in patients with new-onset rheumatoid arthritis: an observational cohort study. <i>Lancet Rheumatology, The</i> , 2021 , 3, e284-e293	14.2	3
179	POS0198 EFFICACY AND SAFETY OF DEUCRAVACITINIB, AN ORAL, SELECTIVE TYROSINE KINASE 2 INHIBITOR, IN PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS: RESULTS FROM A PHASE 2, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL. <i>Annals of the Rheumatic Diseases</i> ,	2.4	3
178	POS1027 EFFICACY AND SAFETY OF GUSELKUMAB, A MONOCLONAL ANTIBODY SPECIFIC TO THE p19-SUBUNIT OF INTERLEUKIN-23, THROUGH 2 YEARS: RESULTS FROM A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY CONDUCTED IN BIOLOGIC-NAÏVE PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS. <i>Annals of the Rheumatic Diseases</i> , 2021 , 80, 783-784	2.4	3
177	Biological DMARDs and disease modification in axial spondyloarthritis: a review through the lens of causal inference. <i>RMD Open</i> , 2021 , 7,	5.9	3
176	The comparison of magnetic resonance imaging and radiographs to assess structural progression over 5 years in hand osteoarthritis. <i>Rheumatology</i> , 2017 , 56, 371-377	3.9	3
175	Development of one general and six country-specific algorithms to assess societal health utilities based on ASAS HI. <i>RMD Open</i> , 2019 , 5, e000872	5.9	3
174	Spinal-pelvic orientation: potential effect on the diagnosis of spondyloarthritis. <i>Rheumatology</i> , 2020 , 59, 84-89	3.9	3
173	Assessment of radiographic progression in patients with rheumatoid arthritis treated with tofacitinib in long-term studies. <i>Rheumatology</i> , 2021 , 60, 1708-1716	3.9	3

172	Structural changes in the sacroiliac joint on MRI and relationship to ASDAS inactive disease in axial spondyloarthritis: a 2-year study comparing treatment with etanercept in EMBARK to a contemporary control cohort in DESIR. <i>Arthritis Research and Therapy</i> , 2021 , 23, 43	5.7	3
171	A Phase III Randomized Study of Apremilast, an Oral Phosphodiesterase 4 Inhibitor, for Active Ankylosing Spondylitis. <i>Journal of Rheumatology</i> , 2021 , 48, 1259-1267	4.1	3
170	LB0001 Dual neutralisation of il-17a and il-17f with bimekizumab in patients with active ankylosing spondylitis (AS): 12-week results from a phase 2b, randomised, double-blind, placebo-controlled, dose-ranging study 2018 ,		3
169	Is radiographic progression in radiographic axial spondyloarthritis related to matrix metalloproteinase degradation of extracellular matrix?. <i>RMD Open</i> , 2018 , 4, e000648	5.9	3
168	Safety and Efficacy of Upadacitinib in Patients With Active Ankylosing Spondylitis and an Inadequate Response to Nonsteroidal Antiinflammatory Drug Therapy: One-Year Results of a Double-Blind, Placebo-Controlled Study and Open-Label Extension. <i>Arthritis and Rheumatology</i> , 2021 ,	9.5	3
167	Do Illness Perceptions and Coping Strategies Change Over Time in Patients Recently Diagnosed With Axial Spondyloarthritis?. <i>Journal of Rheumatology</i> , 2020 , 47, 1752-1759	4.1	2
166	Spinal radiographic progression in axial spondyloarthritis and the impact of classification as nonradiographic versus radiographic disease: Data from the Swiss Clinical Quality Management cohort. <i>PLoS ONE</i> , 2020 , 15, e0230268	3.7	2
165	Integrated longitudinal analysis does not compromise precision and reduces bias in the study of imaging outcomes: A comparative 5-year analysis in the DESIR cohort. <i>Seminars in Arthritis and Rheumatism</i> , 2020 , 50, 1394-1399	5.3	2
164	In patients with axial spondyloarthritis, inflammation on MRI of the spine is longitudinally related to disease activity only in men: 2 years of the axial spondyloarthritis DESIR cohort. <i>Annals of the Rheumatic Diseases</i> , 2018 , 77, 470-472	2.4	2
163	SAT0160 Clinical and Radiographic Outcomes after 2 Years of Sarilumab in Patients with Rheumatoid Arthritis. <i>Annals of the Rheumatic Diseases</i> , 2016 , 75, 724.1-724	2.4	2
162	Alternative diagnoses in patients with chronic back pain not diagnosed with axial spondyloarthritis: data from the SPACE cohort. <i>Annals of the Rheumatic Diseases</i> , 2018 , 77, e34	2.4	2
161	OP0023 Four-year imaging outcomes in axial spondyloarthritis patients treated with certolizumab pegol, including patients with ankylosing spondylitis and non-radiographic axial spondyloarthritis 2017 ,		2
160	Computer-aided evaluation of inflammatory changes over time on MRI of the spine in patients with suspected axial spondyloarthritis: a feasibility study. <i>BMC Medical Imaging</i> , 2017 , 17, 55	2.9	2
159	THU0414 Secukinumab Inhibits Radiographic Progression in Patients with Psoriatic Arthritis: Data from a Phase 3 Randomized, Multicenter, Double-Blind, Placebo-Controlled Study (Future 1). <i>Annals of the Rheumatic Diseases</i> , 2015 , 74, 347.2-348	2.4	2
158	SAT0173 Baseline Parameters Identified in Early, Methotrexate-Na ⁺ Rheumatoid Arthritis Patients with Better Outcomes with Certolizumab Pegol+Methotrexate Compared to Placebo+Methotrexate: Post-Hoc Analyses of C-OPERA, A Randomized, Controlled, Phase 3 Study. <i>Annals of the Rheumatic Diseases</i> , 2015 , 74, 716.2-717	2.4	2
157	Computerised versus conventional methodology of radiographic joint destruction assessment in early rheumatoid arthritis. <i>RMD Open</i> , 2015 , 1, e000148	5.9	2
156	THU0201 Factors Associated with Structural Damage in the Spine, as Measured by X-ray, in Patients with Axial Spondyloarthritis Treated with Certolizumab Pegol Over 96 Weeks. <i>Annals of the Rheumatic Diseases</i> , 2015 , 74, 268.1-268	2.4	2
155	Treatment target and followup measures for patients with gout: a systematic literature review. <i>Journal of rheumatology Supplement, The</i> , 2014 , 92, 55-62		2

154	Introduction: diagnosis and management of gout. Systematic literature reviews of the 3e Initiative 2011-2012. <i>Journal of rheumatology Supplement, The</i> , 2014 , 92, 1-2		2
153	Neutral lateral fingertip-to-floor distance can be derived from height. <i>Annals of the Rheumatic Diseases</i> , 2014 , 73, 1748-9	2.4	2
152	THU0278 The effect of anti-tumor necrosis factor therapy with golimumab on radiographic progression in definite ankylosing spondylitis: 4-year results. <i>Annals of the Rheumatic Diseases</i> , 2013 , 71, 249.2-249	2.4	2
151	FRI0419 Effect of certolizumab pegol on inflammation of spine and sacroiliac joints in patients with axial spondyloarthritis: 12-week magnetic resonance imaging results of rapid-axspa study. <i>Annals of the Rheumatic Diseases</i> , 2013 , 72, A515.2-A516	2.4	2
150	Long-term effects of early treatment in patients with rheumatoid arthritis. <i>Nature Clinical Practice Rheumatology</i> , 2007 , 3, 258-9		2
149	Defining an optimal referral strategy for patients with a suspicion of axial spondyloarthritis: what is really important? Response to: 'Evaluating the ASAS recommendations for early referral of axial spondyloarthritis in patients with chronic low back pain; is one parameter present sufficient for primary care practice?' <i>Annals of the Rheumatic Diseases</i> , 2015 , 74, e19	2.4	2
148	Response to: 'Correspondence on 'EULAR definition of difficult-to-treat rheumatoid arthritis'' by Novella-Navarro. <i>Annals of the Rheumatic Diseases</i> , 2020 ,	2.4	2
147	Validation of the self-administered comorbidity questionnaire adjusted for spondyloarthritis: results from the ASAS-COMOSPA study. <i>Rheumatology</i> , 2020 , 59, 1632-1639	3.9	2
146	Association of lumbosacral transitional vertebra and sacroiliitis in patients with inflammatory back pain suggesting axial spondyloarthritis. <i>Rheumatology</i> , 2020 , 59, 1679-1683	3.9	2
145	Radiographic progression in clinical trials in rheumatoid arthritis: a systemic literature review of trials performed by industry. <i>RMD Open</i> , 2020 , 6,	5.9	2
144	Effects of Denosumab in Japanese Patients With Rheumatoid Arthritis Treated With Conventional Antirheumatic Drugs: 36-month Extension of a Phase III Study. <i>Journal of Rheumatology</i> , 2021 , 48, 1663-1671	4.1	2
143	Response to: 'Correspondence on 'Efficacy of a tight-control and treat-to-target strategy in axial spondyloarthritis: results of the open-label, pragmatic, cluster-randomised TICOSPA trial'' by Cai and Peng. <i>Annals of the Rheumatic Diseases</i> , 2021 ,	2.4	2
142	Response to: 'Denosumab, cortical bone and bone erosion in rheumatoid arthritis' by Rossini et al. <i>Annals of the Rheumatic Diseases</i> , 2016 , 75, e71	2.4	2
141	Construct validity of the Doyle Index in the outcome domain of joint activity in hand osteoarthritis patients. <i>Osteoarthritis and Cartilage</i> , 2016 , 24, S434	6.2	2
140	Associations of lumbar scoliosis with presentation of suspected early axial spondyloarthritis. <i>Seminars in Arthritis and Rheumatism</i> , 2020 , 50, 48-53	5.3	2
139	Development of an environmental contextual factor item set relevant to global functioning and health in patients with axial Spondyloarthritis. <i>Rheumatology</i> , 2021 ,	3.9	2
138	Clinical characteristics of non-radiographic versus radiographic axial spondyloarthritis in Asia and non-radiographic axial spondyloarthritis in other regions: results of the cross-sectional ASAS-COMOSPA study. <i>RMD Open</i> , 2021 , 7,	5.9	2
137	Factors associated with the decision of the rheumatologist to order sacroiliac joints magnetic resonance imaging (SI-MRI) or HLA-B27 testing in the diagnostic work-up of patients with spondyloarthritis in clinical practice. <i>Clinical and Experimental Rheumatology</i> , 2017 , 35, 122-128	2.2	2

136	081 Long-term safety with sarilumab plus conventional synthetic disease-modifying antirheumatic drugs and sarilumab monotherapy in rheumatoid arthritis: an integrated analysis with 9,000 patient-years of follow-up. <i>Rheumatology</i> , 2019 , 58,	3.9	1
135	Outcomes and Findings of the International Rheumatoid Arthritis (RA) BIODAM Cohort for Validation of Soluble Biomarkers in RA. <i>Journal of Rheumatology</i> , 2020 , 47, 796-808	4.1	1
134	SAT0405 No Radiological Sacroiliac Joint Progression after 2 Years of Etanercept Treatment in Non-Radiographic Axial Spondyloarthritis: Data from The Embark Study. <i>Annals of the Rheumatic Diseases</i> , 2016 , 75, 816.2-816	2.4	1
133	SAT0058 Consistency of Radiographic Responses with Sarilumab plus Methotrexate across Subpopulations of Patients with Rheumatoid Arthritis in A Phase 3 Study. <i>Annals of the Rheumatic Diseases</i> , 2016 , 75, 685.1-685	2.4	1
132	DAS steered therapy in clinical practice; cross-sectional results from the METEOR database. <i>BMC Musculoskeletal Disorders</i> , 2016 , 17, 33	2.8	1
131	Response to: 'Inconsistency between supplement and article?' by Babaoglu H. <i>Annals of the Rheumatic Diseases</i> , 2019 , 78, e85	2.4	1
130	Is HLA-B27 increased in patients diagnosed with undifferentiated arthritis? Results from the Leiden early arthritis cohort. <i>Journal of Rheumatology</i> , 2014 , 41, 1948-51	4.1	1
129	SAT0372 Clinical and Imaging Efficacy of Etanercept in Early Non-Radiographic Axial Spondyloarthritis: 48-Week Treatment Data. <i>Annals of the Rheumatic Diseases</i> , 2014 , 73, 728.1-728	2.4	1
128	FRI0019 Clinical Responses by Baseline RA Disease Duration in the AMPLE (Abatacept Versus Adalimumab Comparison in Biologic-Naïve RA Patients with Background Methotrexate) Trial: 2-Year Results. <i>Annals of the Rheumatic Diseases</i> , 2014 , 73, 387.3-388	2.4	1
127	THU0425 Secukinumab Improves Signs and Symptoms of Active Psoriatic Arthritis in a Phase 3 Randomized, Multicenter, Double-Blind, Placebo-Controlled Study Using a Subcutaneous Dosing Regimen (Future 2). <i>Annals of the Rheumatic Diseases</i> , 2015 , 74, 352.3-353	2.4	1
126	THU0202 Clinical Responses and Improvements in Patient-reported Outcomes are Associated with Increased Productivity in the Workplace and at Home in Axial Spondyloarthritis Patients Treated with Certolizumab Pegol. <i>Annals of the Rheumatic Diseases</i> , 2015 , 74, 268.2-269	2.4	1
125	THU0238 A Randomized, Double-Blind, Placebo-Controlled, 16-Week Study of Subcutaneous Golimumab in Patients with Active Nonradiographic Axial Spondyloarthritis. <i>Annals of the Rheumatic Diseases</i> , 2015 , 74, 283.1-283	2.4	1
124	THU0361 Relationship between MRI and Clinical Remission in Patients with Non-Radiographic Axial Spondyloarthritis after Two Years of Adalimumab Therapy. <i>Annals of the Rheumatic Diseases</i> , 2013 , 72, A287.2-A287	2.4	1
123	SAT0099 Preferences of Patients with Spondyloarthritis for the Items of the ASAS Health Index: A Best Worst Scaling. <i>Annals of the Rheumatic Diseases</i> , 2014 , 73, 626.1-626	2.4	1
122	FRI0222 Translation and Cross-Cultural Adaptation of the ASAS Health Index and the Environmental Item Set into 15 Languages. <i>Annals of the Rheumatic Diseases</i> , 2014 , 73, 463.1-463	2.4	1
121	THU0013 Interaction between two common HLA antigens defines a subset of individuals at a very high risk for ankylosing spondylitis. <i>Annals of the Rheumatic Diseases</i> , 2013 , 71, 158.1-158	2.4	1
120	FRI0439 High economic burden of axial spondyloarthritis related to paid work and household productivity at baseline in the rapid-axspa study: differences and similarities between ankylosing spondylitis and non-radiographic axial spondyloarthritis. <i>Annals of the Rheumatic Diseases</i> , 2013 , 72, A523.2-A524	2.4	1
119	SAT0127 Effective disease control following up to 10 years of treatment with adalimumab in patients with long-standing rheumatoid arthritis and an inadequate response to methotrexate: final 10-year results of the DE019 trial. <i>Annals of the Rheumatic Diseases</i> , 2013 , 71, 513.2-513	2.4	1

118	THU0190 Long-Term Impact of Delaying Combination Therapy with Adalimumab Plus Methotrexate by 2 Years in Patients with Early Rheumatoid Arthritis: Final 10-Year Results of the Premier Trial. <i>Annals of the Rheumatic Diseases</i> , 2013 , 72, A227.3-A228	2.4	1
117	FRI0317 CONSENSUS DEFINITIONS FOR MRI LESIONS IN THE SPINE OF PATIENTS WITH AXIAL SPONDYLOARTHRITIS: FIRST ANALYSIS FROM THE ASSESSMENTS IN SPONDYLOARTHRITIS INTERNATIONAL SOCIETY CLASSIFICATION COHORT. <i>Annals of the Rheumatic Diseases</i> , 2020 , 79, 749.2-750	2.4	1
116	Novel approaches in the treatment of ankylosing spondylitis and other spondyloarthritides		1
115	Axial Involvement in Psoriatic Arthritis cohort (AXIS): the protocol of a joint project of the Assessment of SpondyloArthritis international Society (ASAS) and the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA).. <i>Therapeutic Advances in Musculoskeletal</i>	3.8	1
114	FRI0047 STRATEGIES REGARDING GOAL SETTING AND SELF-MANAGEMENT IN DIFFICULT-TO-TREAT RHEUMATOID ARTHRITIS: PRELIMINARY RESULTS OF A SYSTEMATIC LITERATURE REVIEW INFORMING THE 2020 EULAR RECOMMENDATIONS FOR THE MANAGEMENT OF DIFFICULT-TO-TREAT RHEUMATOID ARTHRITIS. <i>Annals of the Rheumatic Diseases</i> , 2020 , 79, 599.2-599	2.4	1
113	SAT0052 THERAPEUTIC STRATEGIES IN DIFFICULT-TO-TREAT RHEUMATOID ARTHRITIS: PRELIMINARY RESULTS OF A SYSTEMATIC LITERATURE REVIEW INFORMING THE 2020 EULAR RECOMMENDATIONS FOR THE MANAGEMENT OF DIFFICULT-TO-TREAT RHEUMATOID ARTHRITIS. <i>Annals of the Rheumatic Diseases</i> , 2020 , 79, 677-677	2.4	1
112	Biomechanical Factors May Be the Main Contributor to Enthesal Changes in Normal Adults. <i>Journal of Rheumatology</i> , 2021 , 48, 618-619	4.1	1
111	Infliximab treatment reduces depressive symptoms in patients with ankylosing spondylitis: an ancillary study to a randomized controlled trial (ASSERT). <i>Arthritis Research and Therapy</i> , 2020 , 22, 225	5.7	1
110	P210 Efficacy and safety of filgotinib for patients with RA with inadequate response to methotrexate: FINCH1 primary outcome results. <i>Rheumatology</i> , 2020 , 59,	3.9	1
109	Which imaging outcomes for axSpA are most sensitive to change? A 5-Year analysis of The DESIR Cohort. <i>Arthritis Care and Research</i> , 2020 ,	4.7	1
108	Long-term Tolerability and Efficacy of Golimumab in Active Non-Radiographic Axial Spondyloarthritis: Results From Open-Label Extension. <i>Rheumatology</i> , 2021 ,	3.9	1
107	Joint tenderness and ultrasound inflammation in DMARD-naïve patients with early rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2021 , 80, 1493-1494	2.4	1
106	Real-time versus static scoring in musculoskeletal ultrasonography in patients with inflammatory hand osteoarthritis. <i>Rheumatology</i> , 2021 ,	3.9	1
105	SAT0375 Certolizumab Pegol for The Treatment of Axial Spondyloarthritis: 4-Year Outcomes from The Rapid-AXSPA Trial. <i>Annals of the Rheumatic Diseases</i> , 2016 , 75, 803.1-803	2.4	1
104	Response to: 'Let's stop fooling ourselves. In RA, only ACR/EULAR criteria define remission and equate with absence of disease!' by Boers. <i>Annals of the Rheumatic Diseases</i> , 2016 , 75, e69	2.4	1
103	OP0227 A Randomized Double-Blind Treatment Strategy Study Evaluating Continuation or Reduced-Frequency Dosing of Certolizumab Pegol versus Withdrawal To Maintain Low Disease Activity in Early RA Patients (C-Early Period 2). <i>Annals of the Rheumatic Diseases</i> , 2016 , 75, 143.2-144	2.4	1
102	Systematic review of rheumatoid arthritis clinical studies: Suboptimal statistical analysis of radiological data. <i>Seminars in Arthritis and Rheumatism</i> , 2019 , 49, 218-221	5.3	1
101	SAT0125 LONG-TERM SAFETY WITH SARILUMAB PLUS CONVENTIONAL SYNTHETIC DISEASE-MODIFYING ANTIRHEUMATIC DRUGS AND SARILUMAB MONOTHERAPY IN RHEUMATOID ARTHRITIS: AN INTEGRATED ANALYSIS WITH 9,000 PATIENT-YEARS OF FOLLOW-UP 2019 ,		1

100	Self-reported painful joint count and assessor-reported tender joint count as instruments to assess pain in hand osteoarthritis. <i>Rheumatology</i> , 2020 , 59, 1094-1098	3.9	1
99	Use of multidimensional composite scores in rheumatology: parsimony versus subtlety. <i>Annals of the Rheumatic Diseases</i> , 2020 ,	2.4	1
98	Determinants of the patient global assessment of well-being in early axial spondyloarthritis: 5-year longitudinal data from the DESIR cohort. <i>Rheumatology</i> , 2021 , 60, 316-321	3.9	1
97	Radiographic sacroiliitis progression in axial spondyloarthritis: central reading of 5 year follow-up data from the Assessment of SpondyloArthritis international Society cohort. <i>Rheumatology</i> , 2021 , 60, 2478-2480	3.9	1
96	Domains to Be Considered for the Core Outcome Set of Axial Spondyloarthritis: Results From a 3-round Delphi Survey. <i>Journal of Rheumatology</i> , 2021 , 48, 1810-1814	4.1	1
95	Radiographic Progression of Structural Joint Damage Over 5 Years of Baricitinib Treatment in Patients With Rheumatoid Arthritis: Results From RA-BEYOND. <i>Journal of Rheumatology</i> , 2021 ,	4.1	1
94	Correspondence on 'Re-examining remission definitions in rheumatoid arthritis: considering the 28-joint Disease Activity Score, C reactive protein level and patient global assessment' by Felson .. <i>Annals of the Rheumatic Diseases</i> , 2022 ,	2.4	1
93	SAT0337 Clinical Response and Remission in Patients with Non-Radiographic Axial Spondyloarthritis after Three Years of Adalimumab Therapy. <i>Annals of the Rheumatic Diseases</i> , 2014 , 73, 714.1-714	2.4	0
92	OP0070 Inequity: Level of Education is Associated with Access to Biologic DMARDs Even in A Country with Highly Developed Social Welfare (NORWAY). <i>Annals of the Rheumatic Diseases</i> , 2014 , 73, 87.1-87	2.4	0
91	FRI0356 Studies on Ageing and the Severity of Radiographic Joint Damage in Rheumatoid Arthritis. <i>Annals of the Rheumatic Diseases</i> , 2015 , 74, 554.3-555	2.4	0
90	OP0160 Response and drug survival of 1st TNF inhibitor in 370 patients with psoriatic arthritis in a real life setting [what is the role of co-medication with methotrexate?]. <i>Annals of the Rheumatic Diseases</i> , 2013 , 71, 108.2-108	2.4	0
89	Correspondence on "Re-examining remission definitions in rheumatoid arthritis: considering the 28-Joint Disease Activity Score, C-reactive protein level and patient global assessment" by Felson et al.. <i>ACR Open Rheumatology</i> , 2022 ,	3.5	0
88	AB0824 WHICH PARAMETERS ARE RELEVANT IN THE IDENTIFYING AXIAL INVOLVEMENT IN PSORIATIC ARTHRITIS? [RESULTS OF A SURVEY AMONG ASAS AND GRAPPA MEMBERS. <i>Annals of the Rheumatic Diseases</i> , 2020 , 79, 1715.1-1716	2.4	0
87	OP0103 DOES GENDER, AGE OR SUBPOPULATION INFLUENCE THE MAINTENANCE OF CLINICAL REMISSION IN AXIAL SPONDYLOARTHRITIS FOLLOWING CERTOLIZUMAB PEGOL DOSE REDUCTION?. <i>Annals of the Rheumatic Diseases</i> , 2020 , 79, 66.1-67	2.4	0
86	Which disease activity outcome measure discriminates best in axial spondyloarthritis? A systematic literature review and meta-analysis. <i>Rheumatology</i> , 2020 , 59, 3990-3992	3.9	0
85	POS0918 EVALUATION OF SPINAL RADIOGRAPHIC PROGRESSION IN PATIENTS WITH RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS RECEIVING IXEKIZUMAB THERAPY OVER 2 YEARS. <i>Annals of the Rheumatic Diseases</i> , 2021 , 80, 720.1-720	2.4	0
84	POS0944 AGE AT ONSET IN AXIAL SPONDYLOARTHRITIS AROUND THE WORLD: DATA FROM THE INTERNATIONAL ASAS-PERSPA STUDY. <i>Annals of the Rheumatic Diseases</i> , 2021 , 80, 735.1-735	2.4	0
83	POS0226 BIMEKIZUMAB LONG-TERM SAFETY AND EFFICACY IN PATIENTS WITH ANKYLOSING SPONDYLITIS: 3-YEAR RESULTS FROM A PHASE 2B STUDY. <i>Annals of the Rheumatic Diseases</i> , 2021 , 80, 332-333	2.4	0

82	Comment on: Development and validation of an alternative ankylosing spondylitis disease activity score when patient global assessment is unavailable: reply. <i>Rheumatology</i> , 2021 , 60, e71-e72	3.9	○
81	Core outcome measurement instrument selection for physical function in hand osteoarthritis using the OMERACT Filter 2.1 process. <i>Seminars in Arthritis and Rheumatism</i> , 2021 , 51, 1311-1311	5.3	○
80	Non-steroidal anti-inflammatory drugs for acute gout. <i>The Cochrane Library</i> , 2021 , 12, CD010120	5.2	○
79	How is early spondyloarthritis defined in the literature? Results from a systematic review. <i>Seminars in Arthritis and Rheumatism</i> , 2022 , 55, 152032	5.3	○
78	Response to: 'The time has come to revisit alternative interpretations of data underlying the EULAR management recommendations for rheumatoid arthritis' by Pirić. <i>Annals of the Rheumatic Diseases</i> , 2017 , 76, e50	2.4	
77	HLA-C*07 in axial spondyloarthritis: data from the German Spondyloarthritis Inception Cohort and the Spondyloarthritis Caught Early cohort. <i>Genes and Immunity</i> , 2019 , 20, 671-677	4.4	
76	Response to: 'Calprotectin is not independent from baseline erosion in predicting radiological progression in early rheumatoid arthritis' by Chevreau. <i>Annals of the Rheumatic Diseases</i> , 2018 , 77, e85	2.4	
75	THU0376 Prevalence of Peripheral and Extra-Articular Disease in Ankylosing Spondylitis versus Non-Radiographic Axial Spondyloarthritis: A Meta-Analysis. <i>Annals of the Rheumatic Diseases</i> , 2016 , 75, 323.2-323	2.4	
74	SAT0528 Development and Validation of A Responsive Ultrasound Joint Inflammation Score for Rheumatoid Arthritis through A Data-Driven Approach. <i>Annals of the Rheumatic Diseases</i> , 2016 , 75, 860.2-860	2.4	
73	THU0168 Baricitinib Inhibits Radiographic Progression of Structural Joint Damage at 1 Year in Patients with Rheumatoid Arthritis (RA) and An Inadequate Response To csDMARDs. <i>Annals of the Rheumatic Diseases</i> , 2016 , 75, 244.2-245	2.4	
72	THU0165 Long-Term Radiographic and Patient-Reported Outcomes Based on Clinical Disease Activity Index Responses with Tofacitinib at 6 Months. <i>Annals of the Rheumatic Diseases</i> , 2016 , 75, 243.1-243	2.4	
71	THU0073 DAS28-CRP and DAS28-ESR Cutoffs for High Disease Activity in Rheumatoid Arthritis Are Not Interchangeable. <i>Annals of the Rheumatic Diseases</i> , 2016 , 75, 205.1-205	2.4	
70	OP0119 Predictors of Radiographic Progression in Early Rheumatoid Arthritis Patients Treated by An Aggressive Tight Control Regime. <i>Annals of the Rheumatic Diseases</i> , 2016 , 75, 100.2-100	2.4	
69	OP0084 Validation of The Asas Health Index: Results of A Multicenter International Study in 23 Countries. <i>Annals of the Rheumatic Diseases</i> , 2016 , 75, 86.2-86	2.4	
68	THU0157 Clinical Outcomes at Week 104 and Analysis of Associated Baseline Factors after An Initial 1 Year of Certolizumab Pegol and MTX Treatment in MTX-Naïve Patients with Early RA: Results from The Second Year of The C-Opera Study. <i>Annals of the Rheumatic Diseases</i> , 2016 , 75, 239.1-239	2.4	
67	SAT0388 Long-Term Efficacy and Tolerability of Golimumab in Active Nonradiographic Axial Spondyloarthritis: Results of The Open-Label Extension of A Randomized, Double-Blind Study. <i>Annals of the Rheumatic Diseases</i> , 2016 , 75, 808.2-809	2.4	
66	SAT0399 Efficacy of Golimumab for Nonradiographic Axial Spondyloarthritis: Subgroup Analysis by Baseline MRI and C-Reactive Protein Status. <i>Annals of the Rheumatic Diseases</i> , 2016 , 75, 813.3-814	2.4	
65	SAT0351 Long-Term Safety and Efficacy of Certolizumab Pegol in Patients with Axial Spondyloarthritis, Including Ankylosing Spondylitis and Non-Radiographic Axial Spondyloarthritis: 96-Week Outcomes of the Rapid-Axspa Trial. <i>Annals of the Rheumatic Diseases</i> , 2014 , 73, 719.3-720	2.4	

64	FRI0326 Efficacy and Safety of Tabalumab, an Anti-B Cell Activating Factor Monoclonal Antibody, in Patients with Rheumatoid Arthritis Who HAD an Inadequate Response to Methotrexate Therapy: Results from A Phase 3 Multicenter, Randomized, Double-Blind Study. <i>Annals of the Rheumatic Diseases</i> , 2014 , 73, 504.2-504	2.4
63	86. Head-to-Head Comparison of Subcutaneous Abatacept Versus Adalimumab on Background Methotrexate in Rheumatoid Arthritis: Blinded Two-Year Results from the Ample Study. <i>Rheumatology</i> , 2014 , 53, i88-i88	3.9
62	SAT0338 Disease Activity and Clinical Response Early in the Course of Treatment PREDICT Long-Term Outcomes in Axial Spondyloarthritis Patients Treated with Certolizumab Pegol. <i>Annals of the Rheumatic Diseases</i> , 2014 , 73, 714.2-715	2.4
61	SAT0339 Asas40 and ASDAS Responses Are Associated with Improved Physical Function, Hrql, and Work Productivity in Patients with Non-Radiographic Axial Spondyloarthritis. <i>Annals of the Rheumatic Diseases</i> , 2014 , 73, 715.1-715	2.4
60	SAT0238 Gender-Attributable Differences in Outcome of Ankylosing Spondylitis: Long-Term Results from the Outcome in Ankylosing Spondylitis International Study. <i>Annals of the Rheumatic Diseases</i> , 2015 , 74, 744.2-745	2.4
59	SAT0185 Clinical and Radiographic Efficacy of Sarilumab Plus Methotrexate in Biologic-Experienced and Biologic-Naïve Patients with Rheumatoid Arthritis in a Phase 3, Randomized, Double-Blind, Placebo-Controlled International Study. <i>Annals of the Rheumatic Diseases</i> , 2015 , 74, 722.1-722	2.4
58	AB1135 Preliminary Definitions of Blare in Axial Spondyloarthritis, Based on Pain, Basdai and ASDAS-CRP: An Asas Initiative. <i>Annals of the Rheumatic Diseases</i> , 2015 , 74, 1281.2-1281	2.4
57	SAT0164 The First Study of Certolizumab Pegol in Combination with Methotrexate in Dmard-Naïve Early Rheumatoid Arthritis Patients Led to Sustained Clinical Response and Inhibition of Radiographic Progression at 52 Weeks: The C-Early Randomized, Double-Blind, Controlled Phase 3 Study. <i>Annals of the Rheumatic Diseases</i> , 2015 , 74, 712.1-712	2.4
56	SAT0619 Ultrasonography Versus Clinical Examination in Early Dmard-Naïve Rheumatoid Arthritis a Comparative Study on the Individual Joint Level. <i>Annals of the Rheumatic Diseases</i> , 2015 , 74, 885.2-885	2.4
55	SAT0564 Clinical Responses in Joint and Skin Outcomes and Patient-Reported Outcomes are Associated with Increased Productivity in the Workplace and at Home in Psoriatic Arthritis Patients Treated with Certolizumab Pegol. <i>Annals of the Rheumatic Diseases</i> , 2015 , 74, 864.2-865	2.4
54	FRI0234 Spinal Radiographic Progression in Early Axial Spondyloarthritis: Data from the Desir Cohort. <i>Annals of the Rheumatic Diseases</i> , 2015 , 74, 509.2-509	2.4
53	FRI0066 The Clinical and Ultrasonographic Presentation of Seronegative RA is More Severe Compared to Seropositive RA in an Inception Cohort of Dmard-Naïve Patients Classified According to the 2010 ACR/Eular Criteria. <i>Annals of the Rheumatic Diseases</i> , 2015 , 74, 443.2-443	2.4
52	SAT0220 Radiographic Progression in Modern RA Trials is Still a Robust Outcome: Results of Comprehensive Sensitivity Analysis in Two Phase 3 Trials with Tofacitinib. <i>Annals of the Rheumatic Diseases</i> , 2015 , 74, 737.2-737	2.4
51	OP0041 MRI Inflammation and Fat Deposition Both Contribute to Syndesmophyte Formation at the Same Site: A Multi-Level Analysis in Patients with Ankylosing Spondylitis. <i>Annals of the Rheumatic Diseases</i> , 2015 , 74, 81.2-82	2.4
50	AB1158 Quality of Life in Patients with Active Peripheral SPA is Similarly Impaired as in Other Rheumatic Diseases and Influenced by Disease Activity But not Disease Duration. <i>Annals of the Rheumatic Diseases</i> , 2015 , 74, 1290.1-1290	2.4
49	SAT0210 X-Ray and MRI Results from A Phase Iib Study of Subcutaneous Anti-Interleukin-6 Monoclonal Antibody Clazakizumab with or without MTX in Adults with Moderate-To-Severe Active RA and Inadequate Response to Conventional DMARDS Including Methotrexate. <i>Annals of the Rheumatic Diseases</i> , 2014 , 73, 665.3-666	2.4
48	SAT0355 Observed Incidence Rates of Uveitis following Certolizumab Pegol Treatment in Patients with Axial Spondyloarthritis. <i>Annals of the Rheumatic Diseases</i> , 2014 , 73, 721.3-722	2.4
47	FRI0425 Similar levels of disease activity in patients with oligoarticular vs. polyarticular peripheral spondyloarthritis. <i>Annals of the Rheumatic Diseases</i> , 2013 , 72, A518.2-A518	2.4

- 46 SAT0261 Which Conventional DMARD to Select in the Treatment of Psoriatic Arthritis (PSA)? Data From Nor-Dmard on 1351 Treatment Courses with Methotrexate (MTX), Sulfasalazine (SSZ) And Leflunomide (LEF). *Annals of the Rheumatic Diseases*, **2013**, 72, A670.2-A671 2.4
- 45 SAT0276 Improvements in Productivity at Paid Work and Within Household, and Increased Participation in Daily Activities After 24 Weeks of Certolizumab Pegol in Patients with Psoriatic Arthritis: Results of Rapid-PSA Study. *Annals of the Rheumatic Diseases*, **2013**, 72, A676.2-A676 2.4
- 44 SAT0473 Defining cut-off values for disease activity states and improvement scores for patient-reported outcomes: the example of the rheumatoid arthritis impact of disease (RAID). *Annals of the Rheumatic Diseases*, **2013**, 71, 632.3-632 2.4
- 43 AB1065 Diagnosing gout without joint fluid aspiration: A systematic literature review using monosodium urate crystals as a reference standard. *Annals of the Rheumatic Diseases*, **2013**, 71, 699.4-699^{3,4} 2.4
- 42 AB0908 Spinal mobility measures are dependent on age in the mobility study. *Annals of the Rheumatic Diseases*, **2013**, 71, 690.14-690 2.4
- 41 FRI0432 Comparison of tests for lumbar flexion and hip function in patients with axial spondyloarthritis and in healthy controls. *Annals of the Rheumatic Diseases*, **2013**, 72, A521.1-A521 2.4
- 40 FRI0438 Disease management of ankylosing spondylitis and non-radiographic axial spondyloarthritis patients is similar in academic and community practice among 654 surveyed rheumatologists. *Annals of the Rheumatic Diseases*, **2013**, 72, A523.1-A523 2.4
- 39 SAT0280 Intermalleolar distance and internal hip rotation are dependent on height in the mobility study. *Annals of the Rheumatic Diseases*, **2013**, 71, 566.3-567 2.4
- 38 FRI0440 Referral patterns and diagnosis of patients with axial spondyloarthritis: results of an international survey. *Annals of the Rheumatic Diseases*, **2013**, 72, A524.1-A524 2.4
- 37 SAT0281 Impact of Imputation Methodology on Radiographic Progression Outcomes in the Rapid-Psa Study Of Certolizumab Pegol In Patients With Psoriatic Arthritis. *Annals of the Rheumatic Diseases*, **2013**, 72, A678.2-A678 2.4
- 36 THU0209 Disease Activity and Structural Damage-Related Differences in Functional Disability in Early and Established Rheumatoid Arthritis. *Annals of the Rheumatic Diseases*, **2013**, 72, A235.1-A235 2.4
- 35 FRI0294 Feasibility of radiographic damage scores in ankylosing spondylitis. *Annals of the Rheumatic Diseases*, **2013**, 71, 413.3-413 2.4
- 34 OP0266 Disease burden is comparable in patients with non-radiographic axial spondyloarthritis and ankylosing spondylitis: Implications for treatment. *Annals of the Rheumatic Diseases*, **2013**, 71, 146.2-146^{2,4} 2.4
- 33 SAT0470 Unblinding the sequence when reading radiographs in rheumatoid arthritis increases efficiency and does not lead to bias. *Annals of the Rheumatic Diseases*, **2013**, 71, 631.2-631 2.4
- 32 SAT0005 RA genetic susceptibility loci are associated with baseline radiographic joint damage in early RA. *Annals of the Rheumatic Diseases*, **2013**, 71, 472.2-472 2.4
- 31 AB0883 Evaluating patient-reported outcomes in patients with early spondyloarthritis in the desir cohort. *Annals of the Rheumatic Diseases*, **2013**, 71, 689.6-689 2.4
- 30 AB0275 14-3-3 eta is an independent marker of joint damage that complements CRP and anti-CCP. *Annals of the Rheumatic Diseases*, **2013**, 71, 653.8-653 2.4
- 29 OP0107 Improvements in Work and Household Productivity after 24 Weeks of Certolizumab Pegol in Treatment of Axial Spondyloarthritis Patients, Including Patients with Ankylosing Spondylitis: Results of Rapid-Axspa Study. *Annals of the Rheumatic Diseases*, **2013**, 72, A87.1-A87 2.4

28	FRI0420 Long term inhibition of IL-17a with secukinumab reduces spinal inflammation but has no influence on fatty lesions as assessed by magnetic resonance imaging in patients with ankylosing spondylitis. <i>Annals of the Rheumatic Diseases</i> , 2013 , 72, A516.1-A516	2.4
27	AB1066 Quality of life and disability assessment in gout: A systematic literature review. <i>Annals of the Rheumatic Diseases</i> , 2013 , 71, 699.5-699	2.4
26	AB0459 Analysis of integrated radiographic data for two long-term, open-label extension studies of adalimumab. <i>Annals of the Rheumatic Diseases</i> , 2013 , 71, 663.15-663	2.4
25	FRI0393 Predictive value of history of digital ulcers in a eustar cohort of patients with systemic sclerosis. <i>Annals of the Rheumatic Diseases</i> , 2013 , 72, A506.1-A506	2.4
24	AB0543 Factors associated with work disability in patients with ankylosing spondylitis. <i>Annals of the Rheumatic Diseases</i> , 2013 , 72, A955.2-A955	2.4
23	THU0191 Achieving Comprehensive Disease Control in Long-Standing or Early Rheumatoid Arthritis Patients Treated with Adalimumab Plus Methotrexate Versus Methotrexate Alone. <i>Annals of the Rheumatic Diseases</i> , 2013 , 72, A228.1-A228	2.4
22	Pain management by pharmacotherapy in inflammatory arthritis. Systematic literature reviews of the 3e Initiative 2010. <i>Journal of rheumatology Supplement, The</i> , 2012 , 90, 1-2	
21	Correspondence on "Re-examining remission definitions in rheumatoid arthritis: considering the 28-Joint Disease Activity Score, C-reactive protein level and patient global assessment" by Felson et al.. <i>Arthritis Care and Research</i> , 2021 ,	4-7
20	FRI0302 WHAT IS THE IMPACT OF DISCREPANCY BETWEEN CENTRAL AND LOCAL READERS IN EVALUATION OF MRI SCANS ON THE CLASSIFICATION OF AXIAL SPONDYLOARTHRITIS? DATA FROM THE ASAS CLASSIFICATION COHORT STUDY. <i>Annals of the Rheumatic Diseases</i> , 2020 , 79, 740.2-741	2.4
19	OP0105 EFFICACY AND SAFETY OF BIMEKIZUMAB IN ANKYLOSING SPONDYLITIS: 48-WEEK PATIENT-REPORTED OUTCOMES FROM A PHASE 2B, RANDOMISED, DOUBLE-BLIND, PLACEBO-CONTROLLED, DOSE-RANGING STUDY. <i>Annals of the Rheumatic Diseases</i> , 2020 , 79, 68-69	2.4
18	OP0315 WHICH RESPONSE OR STATUS CRITERION DISCRIMINATES BEST IN AXSPA?. <i>Annals of the Rheumatic Diseases</i> , 2020 , 79, 194.1-195	2.4
17	OP0078 MAPPING FROM THE ANKYLOSING SPONDYLITIS DISEASE ACTIVITY SCORE (ASDAS) TO EQ5D IN PATIENTS WITH AXIAL SPONDYLOARTHRITIS. <i>Annals of the Rheumatic Diseases</i> , 2020 , 79, 52.1-53 [†]	2.4
16	SAT0384 REPLACEMENT OF RADIOGRAPHIC SACROILITIS BY MRI STRUCTURAL LESIONS: WHAT IS THE IMPACT ON CLASSIFICATION OF AXIAL SPONDYLOARTHRITIS IN THE ASAS CLASSIFICATION COHORT?. <i>Annals of the Rheumatic Diseases</i> , 2020 , 79, 1140.2-1141	2.4
15	SAT0587 MACHINE-LEARNING DERIVED ALGORITHMS FOR OUTCOMES PREDICTION IN RHEUMATIC DISEASES: APPLICATION TO RADIOGRAPHIC PROGRESSION IN EARLY AXIAL SPONDYLOARTHRITIS. <i>Annals of the Rheumatic Diseases</i> , 2020 , 79, 1252.2-1253	2.4
14	POS0182 MINIMAL CLINICALLY IMPORTANT IMPROVEMENT (MCII) AND PATIENT ACCEPTABLE SYMPTOM STATE (PASS) FOR PAIN AND FUNCTION INSTRUMENTS IN HAND OSTEOARTHRITIS (OA). <i>Annals of the Rheumatic Diseases</i> , 2021 , 80, 304.2-305	2.4
13	OP0227 EFFICACY OF DEUCRAVACITINIB, AN ORAL, SELECTIVE TYROSINE KINASE 2 INHIBITOR, IN MUSCULOSKELETAL MANIFESTATIONS OF ACTIVE PSORIATIC ARTHRITIS IN A PHASE 2, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL. <i>Annals of the Rheumatic Diseases</i> ,	2.4
12	OP0251 DATA-DRIVEN DEFINITIONS BASED ON INFLAMMATORY LESIONS FOR A POSITIVE MRI OF THE SPINE CONSISTENT WITH AXIAL SPONDYLOARTHRITIS. <i>Annals of the Rheumatic Diseases</i> , 2021 , 80, 153.1-153	2.4
11	POS0032 SCORING MRI STRUCTURAL LESIONS IN SACROILIAC JOINTS OF PATIENTS WITH AXIAL SPONDYLOARTHRITIS: HOW MANY SLICES ARE OPTIMAL?. <i>Annals of the Rheumatic Diseases</i> , 2021 , 80, 221.1-221	2.4

10	POS0954 QUALITY OF LIFE IN CHRONIC BACK PAIN PATIENTS, A 2-YEAR COMPARISON BETWEEN PATIENTS WITH AND WITHOUT A DIAGNOSIS OF AXIAL SPONDYLOARTHRITIS: DATA FROM THE SPONDYLOARTHRITIS CAUGHT EARLY COHORT. <i>Annals of the Rheumatic Diseases</i> , 2021 , 80, 741-741	2.4
9	OP0047 IDENTIFICATION OF CLINICAL PHENOTYPES IN PATIENTS WITH AXIAL SPONDYLOARTHRITIS, PERIPHERAL SPONDYLOARTHRITIS AND PSORIATIC ARTHRITIS ACCORDING TO PERIPHERAL MUSCULOSKELETAL MANIFESTATIONS: A CLUSTER ANALYSIS IN THE INTERNATIONAL ASAS-PROSPA STUDY. <i>Annals of the Rheumatic Diseases</i> , 2021 , 80, 741-741	2.4
8	POS0975 CLINICAL CHARACTERISTICS OF NONRADIOGRAPHIC AXIAL SPONDYLOARTHRITIS IN ASIAN COUNTRIES COMPARED TO OTHER REGIONS: RESULTS OF THE INTERNATIONAL CROSS-SECTIONAL ASAS-COMOSPA STUDY. <i>Annals of the Rheumatic Diseases</i> , 2021 , 80, 753.2-754	2.4
7	FRI0090 BMI and Tender Joints Are Predictors of Not Reaching Sustained Remission in Patients Participating in An Aggressive Treat-To-Target Study. <i>Annals of the Rheumatic Diseases</i> , 2016 , 75, 460.1-460	2.4
6	SAT0149 Radiographic Outcomes in Patients Achieving Clinical Remission or Low Disease Activity in A Phase 3 Study of Sarilumab plus Methotrexate in Patients with Active, Moderate-To-Severe Rheumatoid Arthritis. <i>Annals of the Rheumatic Diseases</i> , 2016 , 75, 719.1-719	2.4
5	FRI0433 Factors Associated with Elevated Acute Phase Reactants in Patients with Recent Inflammatory Back Pain: Impact of C Reactive Protein on The Phenotype of Patients. Data from The Prospective Multicenter French Cohort Desir. <i>Annals of the Rheumatic Diseases</i> , 2016 , 75, 592.2-592	2.4
4	SAT0389 Long-Term Improvements in Workplace and Household Productivity and Social Participation over 4 Years of Certolizumab Pegol Treatment in Patients with Axial Spondyloarthritis, Including Ankylosing Spondylitis and Non-Radiographic Axial Spondyloarthritis. <i>Annals of the Rheumatic Diseases</i> , 2016 , 75, 809.1-809	2.4
3	THU0163 Early Response as A Predictor of Long-Term Clinical Response in DMARD-Naïve Patients with Severe, Active and Progressive RA Treated with Certolizumab Pegol plus Optimized MTX versus Optimized MTX Alone. <i>Annals of the Rheumatic Diseases</i> , 2016 , 75, 242.1-242	2.4
2	Response to: 'Reactive arthritis, a missing link: comment on the recent article from Sepriano ' by Zeidler and Hudson. <i>Annals of the Rheumatic Diseases</i> , 2020 ,	2.4
1	Response to: 'The GRAPPA-OMERACT initiative to standardise outcomes in Psoriatic Arthritis clinical trials and longitudinal observational studies' by Tillet. <i>Annals of the Rheumatic Diseases</i> , 2018 , 77, e24	2.4